PRODUCT MONOGRAPH

PrLEVITRA®

Vardenafil tablets

5 mg, 10 mg, 20 mg of vardenafil, as vardenafil hydrochloride

Bayer Standard
cyclic GMP-Specific Phosphodiesterase Type 5 Inhibitor

Treatment of Erectile Dysfunction

Bayer Inc.
2920 Matheson Boulevard East
Mississauga, Ontario
L4W 5R6
http://www.bayer.ca

Date of Revision: February 25, 2020

Submission Control No: 234111
© 2020, Bayer Inc.
® TM see www.bayer.ca/tm-mc
# Table of Contents

## PART I: HEALTH PROFESSIONAL INFORMATION
- SUMMARY PRODUCT INFORMATION .......................................................... 3
- INDICATIONS AND CLINICAL USE .............................................................. 3
- CONTRAINDICATIONS .................................................................................. 3
- WARNINGS AND PRECAUTIONS ................................................................. 4
- ADVERSE REACTIONS ................................................................................... 9
- DRUG INTERACTIONS .................................................................................. 11
- DOSAGE AND ADMINISTRATION ............................................................... 15
- OVERDOSAGE ............................................................................................. 15
- TREATMENT OF PRIAPISM ....................................................................... 16
- ACTION AND CLINICAL PHARMACOLOGY ............................................. 16
- STORAGE AND STABILITY ......................................................................... 21
- DOSAGE FORMS, COMPOSITION AND PACKAGING .............................. 21

## PART II: SCIENTIFIC INFORMATION
- PHARMACEUTICAL INFORMATION ............................................................. 22
- CLINICAL TRIALS ....................................................................................... 22
- DETAILED PHARMACOLOGY .................................................................... 35
- MICROBIOLOGY ......................................................................................... 41
- TOXICOLOGY .............................................................................................. 41
- REFERENCES ............................................................................................... 47

## PART III: CONSUMER INFORMATION
- .................................................................................................................. 50
**LEVITRA®**

vardenafil tablets

PART I: HEALTH PROFESSIONAL INFORMATION

SUMMARY PRODUCT INFORMATION

Table 1: Summary Product Information

<table>
<thead>
<tr>
<th>Route of Administration</th>
<th>Dosage Form / Strength</th>
<th>Clinically Relevant Nonmedicinal Ingredients</th>
</tr>
</thead>
<tbody>
<tr>
<td>oral</td>
<td>Tablets / 5 mg, 10 mg, 20 mg of vardenafil, as vardenafil hydrochloride</td>
<td>None. For a complete listing see DOSAGE FORMS, COMPOSITION AND PACKAGING section.</td>
</tr>
</tbody>
</table>

INDICATIONS AND CLINICAL USE

LEVITRA (vardenafil tablets) is indicated for:

- Treatment of erectile dysfunction (difficulties or the inability to achieve or maintain penile erection sufficient for satisfactory sexual performance).

Special Populations

Pregnant and Nursing Women: LEVITRA is not indicated for use in women. There are no trials of LEVITRA in pregnant women.

Pediatrics (< 18 years of age): LEVITRA is not indicated for use in individuals less than 18 years old.

Geriatrics (≥ 65 years of age): A starting dose of 5 mg LEVITRA should be considered in patients 65 years and older. On average, elderly males (65 years and over) had a 52% higher vardenafil AUC than younger males (18-45 years); however, this difference was not statistically significant. (See ACTION AND CLINICAL PHARMACOLOGY and DETAILED PHARMACOLOGY.)

CONTRAINDICATIONS

- Patients who are hypersensitive to this drug or to any ingredient in the formulation or component of the container. For a complete listing, see the DOSAGE FORMS, COMPOSITION AND PACKAGING section of the product monograph.
Consistent with the effects of PDE5 inhibition on the nitric oxide/cyclic guanosine monophosphate pathway, PDE5 inhibitors may potentiate the hypotensive effects of nitrates, and therefore **co-administration of LEVITRA (vardenafil tablets) with nitrates and nitric oxide donors is contraindicated.**

In a patient prescribed LEVITRA (vardenafil tablets), where nitrate administration is deemed medically necessary in a life-threatening situation, at least 24 hours should have elapsed after the last dose of LEVITRA (vardenafil tablets) before nitrate administration is considered. In such circumstances, nitrates should only be administered under close medical supervision with appropriate hemodynamic monitoring.

Concomitant use of LEVITRA (vardenafil tablets) with medicinal products containing cobicistat, HIV protease inhibitors such as indinavir, ritonavir, saquinavir, or atazanavir, and combinations of these, ketoconazole, or itraconazole is contraindicated, as they are potent inhibitors of CYP3A4 (see **WARNINGS AND PRECAUTIONS** and **DOSAGE AND ADMINISTRATION**).

LEVITRA (vardenafil tablets) is contraindicated in patients with erectile dysfunction with a previous episode of non-arteritic anterior ischaemic optic neuropathy (NAION) (see **WARNINGS AND PRECAUTIONS**).

The co-administration of PDE5 inhibitors, including LEVITRA, with guanylate cyclase stimulators, such as riociguat, is contraindicated as it may lead to potentially life-threatening episodes of symptomatic hypotension or syncope (see **DRUG INTERACTIONS**).

**WARNINGS AND PRECAUTIONS**

**General**

The evaluation of erectile dysfunction should include a determination of potential underlying causes, a medical assessment and the identification of appropriate treatment.

Before prescribing LEVITRA (vardenafil tablets), it is important to note the following:

- LEVITRA has not been administered to patients with bleeding disorders or significant active peptic ulceration. Therefore LEVITRA should be administered to these patients after careful benefit-risk assessment. In humans, LEVITRA has no effect on bleeding time alone or with acetylsalicylic acid (ie, **ASPIRIN®**). In vitro studies with human platelets indicate that LEVITRA does not inhibit platelet aggregation induced by a variety of platelet agonists. A small, concentration-dependent, enhancement of the anti-aggregation effects of a nitric oxide donor, nitroprusside, was observed with supra-therapeutic concentrations of LEVITRA in the presence of platelet agonists. The bleeding time in rats with a combination of heparin and vardenafil was not different from that observed with heparin alone. However, this interaction has not been studied in humans.

- Treatment for erectile dysfunction should generally be used with caution in patients with anatomical deformation of the penis (such as angulation, cavernosal fibrosis or Peyronie's disease) or in patients who have conditions that may predispose them to priapism (such as sickle cell anemia, multiple myeloma, or leukemia).
LEVITRA has not been studied in patients with CNS disease (other than spinal cord injury), hypoactive sexual desire, or in patients who have undergone pelvic surgery (except nerve sparing prostatectomy), pelvic trauma, or radiotherapy.

Post-marketing reports of sudden loss of vision have occurred rarely, in temporal association with the use of PDE5 inhibitors. It is not clear whether these are related directly to the use of PDE5 inhibitors or to other factors. There may be an increased risk to patients who have already experienced Non-arteritic Anterior Ischemic Optic Neuropathy (NAION).

**Cardiovascular**

Physicians should consider the cardiovascular status of their patients, since there is a degree of cardiac risk associated with sexual activity. In men for whom sexual activity is not recommended because of their underlying cardiovascular status, including uncontrolled hypertension (with BP > 140/90 mmHg), any treatment for erectile dysfunction, including LEVITRA, generally should not be used. Physicians are advised to consult the recommendations of the Princeton Consensus Panel (DeBusk et al. Am J Cardiol 2000;86:175-81). The following groups of patients with cardiovascular disease were not included in clinical trials:

- patients with a myocardial infarction or stroke within the last 6 months,
- patients with unstable angina pectoris or acute myocardial ischemia,
- patients with uncontrolled arrhythmias, hypotension (<90/50 mmHg), uncontrolled hypertension (>170/110 mmHg),
- patients with symptomatic postural hypotension in the last six months.

LEVITRA has vasodilator properties which may result in mild and transient decreases in blood pressure. Patients with left ventricular outflow obstruction, eg, aortic stenosis and idiopathic hypertrophic subaortic stenosis, can be sensitive to the action of vasodilators, including Type 5 phosphodiesterase inhibitors.

Patients should be stable on alpha-blocker therapy before prescribing LEVITRA.

Patients receiving alpha-blocker therapy should be initiated at the lowest dose of 5 mg LEVITRA.

**Congenital and Acquired QT Prolongation**

In a study of the effect of LEVITRA on the QT interval in 59 healthy males, therapeutic (10 mg) and supratherapeutic (80 mg) doses of LEVITRA produced minimal increases in QTc interval. (See ACTION AND CLINICAL PHARMACOLOGY, and DETAILED PHARMACOLOGY.) In a post-marketing study evaluating the effect of combining LEVITRA with another drug of comparable QT effect (400 mg gatifloxacin), it was shown that the drug combination produced an additive QT effect when compared with either drug alone. (See DRUG INTERACTIONS, ACTION AND CLINICAL PHARMACOLOGY, and DETAILED PHARMACOLOGY.) These observations should be considered in clinical decisions when prescribing LEVITRA to patients with known history of QT prolongation or patients who are taking medications known to prolong the QT interval. Patients with congenital QT prolongation (long QT syndrome) and those taking Class IA (eg,
quinidine, procainamide) or Class III (eg, amiodarone, sotalol) antiarrhythmic medications should avoid using LEVITRA.

**Hepatic**

No dose adjustment is required in patients with mild hepatic impairment. (See **WARNINGS AND PRECAUTIONS, ACTION AND CLINICAL PHARMACOLOGY, and DETAILED PHARMACOLOGY**.)

In patients with mild hepatic impairment (Child-Pugh A), following a 10 mg dose of LEVITRA, the vardenafil AUC was increased 17% and the maximum concentration (C\text{max}) was increased 22%, compared to healthy male volunteers. In patients with moderate impairment (Child-Pugh B), following a 10 mg dose of LEVITRA, the vardenafil AUC was increased 160% and C\text{max} was increased 133%, compared to healthy male volunteers.

In patients with moderate hepatic impairment, a 5 mg starting dose of LEVITRA is recommended, which may subsequently be increased to a maximum dose of 10 mg, based on tolerability and efficacy. (See **WARNINGS AND PRECAUTIONS, DOSAGE AND ADMINISTRATION, and ACTION AND CLINICAL PHARMACOLOGY**.)

There are no controlled clinical data on the efficacy and safety of LEVITRA in severe hepatic impairment; its use is therefore not recommended until further information is available.

**Ophthalmologic**

There are no controlled clinical data on the efficacy and safety of LEVITRA in known hereditary degenerative retinal disorders such as retinitis pigmentosa; its use is therefore not recommended until further information is available.

Physicians should advise patients to stop use of all phosphodiesterase type 5 (PDE5) inhibitors, including LEVITRA, and seek medical attention in the event of sudden loss of vision in one or both eyes. Such an event may be a sign of nonarteritic anterior ischemic optic neuropathy (NAION), a rare condition and a cause of decreased vision, including permanent loss of vision, that has been reported rarely postmarketing in temporal association with the use of all PDE5 inhibitors. Based on published literature, the annual incidence of NAION is 2.5 - 11.8 cases per 100,000 in males aged ≥50. An observational case-crossover study evaluated the risk of NAION when PDE5 inhibitor use, as a class, occurred immediately before NAION onset (within 5 half-lives), compared to PDE5 inhibitor use in a prior time period. The results suggest an approximate 2-fold increase in the risk of NAION, with a risk estimate of 2.15 (95% CI 1.06, 4.34). A similar study reported a consistent result, with a risk estimate of 2.27 (95% CI 0.99, 5.20). Other risk factors for NAION, such as the presence of “crowded” optic disc, may have contributed to the occurrence of NAION in these studies.

Neither the rare postmarketing reports, nor the association of PDE5 inhibitor use and NAION in the observational studies, substantiate a causal relationship between PDE5 inhibitor use and NAION (see **ADVERSE REACTIONS**).

Physicians should consider whether their patients with underlying NAION risk factors could be adversely affected by use of PDE5 inhibitors. Individuals who have already experienced NAION are at increased risk of NAION recurrence. Therefore, PDE5 inhibitors, including LEVITRA, should be
used with caution in these patients and only when the anticipated benefits outweigh the risks. Individuals with “crowded” optic disc are also considered at greater risk for NAION compared to the general population, however, evidence is insufficient to support screening of prospective users of PDE5 inhibitors, including LEVITRA, for this uncommon condition.

**Otologic**

Sudden decrease or loss of hearing has been reported in a few post-marketing and clinical trial cases with the use of PDE5 inhibitors, including LEVITRA. These events, which may be accompanied by tinnitus and dizziness, have been reported in temporal association to the intake of PDE5 inhibitors, including LEVITRA. In some of the cases, medical conditions and other factors were reported that may have also played a role in the otologic adverse events. In many cases, medical follow-up information was limited. It is not possible to determine whether these events are related directly to the use of PDE5 inhibitors or to other factors (see ADVERSE REACTIONS, Post-Market Adverse Drug Reactions and PART III: CONSUMER INFORMATION). Physicians should advise patients to stop taking LEVITRA and seek prompt medical attention in case of sudden decrease or loss of hearing.

**Renal**

No dose adjustment is required in patients with renal impairment. In patients with mild, moderate, or severe renal impairment, the pharmacokinetics of LEVITRA were similar to that of control groups with normal renal function. LEVITRA pharmacokinetics have not been evaluated in patients requiring dialysis.

There are no controlled clinical data on the efficacy and safety of LEVITRA in end stage renal disease requiring dialysis; its use is therefore not recommended until further information is available.

**Sexual Function/Reproduction**

Prolonged erection greater than 4 hours and priapism (painful erections greater than 6 hours in duration) have been reported infrequently with the use of PDE5 inhibitors, including LEVITRA. The incidence of priapism may increase when PDE5 inhibitors are used in combination with intrapenile injections containing vasoactive agents, or other drugs with a known risk of priapism. In the event of an erection that persists longer than 4 hours, the patient should seek immediate medical assistance. If priapism is not treated immediately, penile tissue damage and permanent loss of potency could result. (See TREATMENT OF PRIAPISM.)

The safety and efficacy of combinations of LEVITRA with other agents for the treatment of erectile dysfunction have not been studied. Therefore, the use of such combinations is not recommended.

**Information for Patients**

Physicians should discuss with patients the contraindications of LEVITRA with regular and/or intermittent use of organic nitrates. Patients should be advised that concomitant use of LEVITRA and nitrates could cause a sudden drop in blood pressure, dizziness, syncope, heart attack, or stroke.
Physicians should advise patients to stop taking PDE5 inhibitors, including LEVITRA, and seek prompt medical attention in the event of sudden decrease or loss of hearing. These events, which may be accompanied by tinnitus and dizziness, have been reported in temporal association to the intake of PDE5 inhibitors, including LEVITRA. It is not possible to determine whether these events are related directly to the use of PDE5 inhibitors or to other factors. (See ADVERSE REACTIONS.)

Physicians should consider the potential cardiac risk of sexual activity in patients with pre-existing cardiovascular disease. Patients who experience symptoms upon initiation of sexual activity should be advised to refrain from further sexual activity and should report the episode to their physician.

Physicians should discuss with patients the appropriate use of LEVITRA and its potential benefits. The patient should be told that sexual stimulation is necessary for an erection if LEVITRA is consumed. Patients should be told that LEVITRA should be taken approximately 25-60 minutes before sexual activity and no more than the recommended dose should be taken. They should be advised to contact their physician for dose adjustment if they are not satisfied with the quality of their erection or if they have an undesirable effect. Patients should be counselled about the importance of notifying their physicians about other medications they have been prescribed, including LEVITRA. Physicians should counsel patients that the concomitant use of PDE5 inhibitors, including LEVITRA with alpha-blockers may lead to symptomatic hypotension in some patients. PDE5 inhibitor therapy should only be initiated if the patient is stable on his alpha-blocker therapy. Patients should be advised that vardenafil may be administered at any time with tamsulosin. With other alpha-blockers, a time separation of dosing should be considered when vardenafil is prescribed concomitantly. In those patients already taking an optimized dose of vardenafil, alpha-blocker therapy should be initiated at the lowest dose. A stepwise increase in alpha-blocker dose may be associated with further lowering of blood pressure in patients taking a PDE5 inhibitor, including vardenafil. Patients should be advised that after stable concomitant therapy is established, vardenafil may be titrated as needed and tolerated. (See DOSAGE AND ADMINISTRATION.)

Physicians should inform patients that erectile disturbances including prolonged erections greater than 4 hours and priapism have been reported with PDE5 inhibitors, including LEVITRA. Patients who experience erections lasting 4 hours or more should be instructed to seek immediate medical assistance. If priapism is not treated immediately, penile tissue damage and permanent loss of potency may result. The incidence of priapism may increase when PDE5 inhibitors, including LEVITRA, are used in combination with intra-penile injections containing vasoactive agents (eg, CAVERJECT™).

LEVITRA should be used with caution in patients who have conditions that might predispose them to priapism (such as sickle cell anemia, multiple myeloma, or leukemia), or in patients with anatomical deformation of the penis (such as angulation, cavernosal fibrosis or Peyronie’s disease).

Non-arteritic Anterior Ischemic Optic Neuropathy (NAION) has been reported rarely in postmarketing surveillance with PDE5 inhibitors, including vardenafil.

Physicians should discuss with their patients the increased risk of NAION before prescribing LEVITRA. If an individual experiences reduction or loss of vision in one or both eyes after the use of LEVITRA, he should immediately report the episode to his physician.
The use of LEVITRA offers no protection against sexually transmitted diseases. Counselling of patients about the protective measures necessary to guard against sexually transmitted diseases, including Human Immunodeficiency Virus (HIV), should be considered.

ADVERSE REACTIONS

Adverse Drug Reaction Overview

LEVITRA (vardenafil tablets) was administered to over 7800 patients (ages 18-89 years) during clinical trials worldwide. Over 625 patients were treated for 6 months and 557 were treated for at least one year. In placebo-controlled clinical trials, the discontinuation rate due to adverse events was low for LEVITRA (3.5% compared to 1.2% for placebo). The most common reasons for discontinuation in the LEVITRA-treated patients were headache (0.9%) and flushing (0.5%). Adverse events with LEVITRA were generally transient, mild to moderate in nature, and decreased with continued dosing.

Clinical Trial Adverse Drug Reactions

Because clinical trials are conducted under very specific conditions, the adverse reaction rates observed in the clinical trials may not reflect the rates observed in practice and should not be compared to the rates in the clinical trials of another drug. Adverse drug reaction information from clinical trials is useful for identifying drug-related adverse events and for approximating rates.

When LEVITRA was taken as recommended, the following adverse events in Table 2 were reported in placebo-controlled clinical trials:

Table 2: Adverse Events Reported by ≥1% of Patients Treated with LEVITRA and More Frequent on Drug than Placebo in All Placebo-controlled Trials of 5 mg, 10 mg, and 20 mg LEVITRA

<table>
<thead>
<tr>
<th>Condition</th>
<th>LEVITRA N= 3293 (%)</th>
<th>Placebo N= 1861 (%)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Gastrointestinal Disorders</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Dyspepsia</td>
<td>2.5</td>
<td>&lt;0.1</td>
</tr>
<tr>
<td>Nausea</td>
<td>1.2</td>
<td>0.3</td>
</tr>
<tr>
<td>Nervous System</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Dizziness</td>
<td>1.6</td>
<td>0.3</td>
</tr>
<tr>
<td>Headache</td>
<td>10.4</td>
<td>2.0</td>
</tr>
<tr>
<td>Respiratory, Thoracic and Mediastinal</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Nasal congestion, (including edema mucosal, rhinitis, rhinorhea)</td>
<td>4</td>
<td>0.3</td>
</tr>
<tr>
<td>Vascular</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Flushing (including hot flush, feeling hot, erythema)</td>
<td>11.3</td>
<td>0.8</td>
</tr>
</tbody>
</table>

Less Common Clinical Trial Adverse Drug Reactions (<1%)

The following additional adverse events where a causal relationship is uncertain (but plausible) occurred in <1% of patients receiving LEVITRA in all clinical trials:

Body as a Whole: abdominal pain (including abdominal pain upper), asthenia, back pain, chest pain, face edema, hypersensitivity, influenza (including influenza like illness), laryngeal edema, neck pain, photosensitivity reaction.
**Cardiovascular:** angina pectoris, hypertension, hypotension, myocardial ischemia, palpitations, postural hypotension, syncope, tachycardia (including heart rate increased).

**Gastrointestinal including related Investigations:** abnormal liver function tests (including hepatic enzyme increased, alanine aminotransferase increased, aspartate aminotransferase increased), diarrhea, dry mouth, dysphagia, esophagitis (including reflux esophagitis), gastritis, gastroesophageal reflux disease, GGTP increased, increased creatinine kinase, nausea, vomiting.

**Musculoskeletal:** arthralgia, muscle rigidity, myalgia.

**Nervous:** anxiety, burning sensation, dizziness, feeling abnormal, hypesthesia, insomnia, paresthesia, somnolence, vertigo, seizure, transient global amnesia.

**Respiratory, Thoracic and Mediastinal:** dyspnea, epistaxis, sinus congestion (including sinus pain).

**Skin and Appendages:** hyperhidrosis, pruritus, rash, sweating.

**Special Senses:** chromatopsia (including cyanopsia), conjunctivitis (including eye redness), eye pain (including eye irritation, abnormal sensation in eye), intraocular pressure increased, lacrimation increased, photophobia, sudden decrease or loss of hearing, tinnitus, vision blurred, visual disturbance (including visual brightness).

**Urogenital:** ejaculation disorder (including premature ejaculation), priapism (including prolonged or painful erections).

**Post-Market Adverse Drug Reactions**

Myocardial infarction (MI) has been reported in temporal association with the use of LEVITRA and sexual activity, but it is not possible to determine whether MI is related directly to vardenafil, to sexual activity, to the patient's underlying cardiovascular disease, or to a combination of these factors.

From post-marketing experience with drugs of this class, the following serious adverse events have been reported in temporal association with the use of the PDE5 inhibitors: abnormal accommodation, abnormal vision, amnesia, anxiety, cardiovascular hemorrhage, cerebrovascular hemorrhage, decreased vision, hematemesis, hematuria, intraocular hemorrhage, pulmonary hemorrhage, seizure, sudden cardiac death, temporary vision loss, and ventricular arrhythmia.

Cases of sudden decrease or loss of hearing have been reported in temporal association with the use of PDE5 inhibitors including LEVITRA. In some cases, medical conditions and other factors were reported that may have also played a role in the otologic adverse events. In many cases, medical follow-up information was limited. It is not possible to determine whether these reported events are related directly to the use of LEVITRA, to the patient’s underlying risk factors for hearing loss, a combination of these factors, or to other factors. (See WARNINGS AND PRECAUTIONS, ADVERSE REACTIONS, and PART III: CONSUMER INFORMATION.)

**Special senses:** nonarteritic anterior ischemic optic neuropathy, retinal vein occlusion, visual field defect.
Non-arteritic Anterior Ischemic Optic Neuropathy (NAION) has been reported rarely in post-marketing surveillance with PDE5 inhibitors, including vardenafil. Two observational case-crossover studies evaluated the risk of NAION after PDE5 inhibitor use, as a class. The results suggest an approximate 2-fold increase in the risk of NAION. However, a causal relationship between PDE5 inhibitor use and NAION has not been substantiated (see **WARNINGS AND PRECAUTIONS**).

**DRUG INTERACTIONS**

<table>
<thead>
<tr>
<th>Serious Drug Interactions</th>
</tr>
</thead>
</table>
| • Consistent with the effects of PDE5 inhibition on the nitric oxide/cyclic guanosine monophosphate pathway, PDE5 inhibitors may potentiate the hypotensive effects of nitrates, and therefore **co-administration of LEVITRA (vardenafil tablets) with nitrates and nitric oxide donors is contraindicated.**  
In a patient prescribed LEVITRA (vardenafil tablets), where nitrate administration is deemed medically necessary in a life-threatening situation, at least 24 hours should have elapsed after the last dose of LEVITRA (vardenafil tablets) before nitrate administration is considered. In such circumstances, nitrates should only be administered under close medical supervision with appropriate hemodynamic monitoring. |
| • Concomitant use of LEVITRA (vardenafil tablets) with medicinal products containing cobicistat, HIV protease inhibitors such as indinavir, ritonavir, saquinavir, or atazanavir, and combinations of these, ketoconazole, or itraconazole is contraindicated, as they are potent inhibitors of CYP3A4 (see **WARNINGS AND PRECAUTIONS** and **DOSAGE AND ADMINISTRATION**). |
| • The co-administration of PDE5 inhibitors, including LEVITRA, with guanylate cyclase stimulators, such as riociguat, is contraindicated as it may lead to potentially life-threatening episodes of symptomatic hypotension or syncope (see **DRUG INTERACTIONS**). |

**Overview**

**CYP3A4 Inhibitors:** Vardenafil is metabolized predominantly by hepatic enzymes via cytochrome P450 (CYP) isoform 3A4, with some contribution from CYP3A5 and CYP2C isoforms. Therefore, inhibitors of these enzymes may reduce vardenafil clearance. Concomitant use of LEVITRA with medicinal products containing cobicistat, HIV protease inhibitors such as indinavir, ritonavir, saquinavir, or atazanavir, and combinations of these, ketoconazole, and itraconazole is contraindicated, as they are potent inhibitors of CYP3A4. (See **CONTRAINDICATIONS** and **DOSAGE AND ADMINISTRATION**.)

**Antihypertensive Agents:** The potential for LEVITRA to augment the hypotensive effects of antihypertensive agents was examined in a clinical pharmacology study and in placebo-controlled clinical trials.

LEVITRA (20 mg), when co-administered with slow-release nifedipine (30 mg or 60 mg once daily to hypertensive patients), did not affect the relative AUC or C\text{max} of nifedipine, a drug that is metabolized via CYP3A4. LEVITRA (20 mg) produced mean additional blood pressure reductions of 5.9 mmHg and 5.2 mmHg for supine systolic and diastolic blood pressure, respectively, compared to placebo.
In the placebo-controlled studies of 5, 10, and 20 mg LEVITRA, a total of 41% of patients on placebo and 42% of patients on LEVITRA received at least one antihypertensive medication during their treatment with study medication. Major classes of antihypertensive agents were represented, including: calcium channel blockers (N=353), ACE inhibitors (N=650), beta-blockers (N=346), angiotensin receptor blockers (N=188), and diuretics (N=312). Analysis of these data showed no difference in adverse events, cardiovascular adverse events or discontinuations due to adverse events, in patients taking LEVITRA with or without antihypertensive medications.

**Riociguat:** Animal models showed an additive systemic blood pressure lowering effect when sildenafil or vardenafil was combined with riociguat. Increasing the dose of sildenafil or vardenafil resulted in a greater than proportional decrease in systemic blood pressure in some cases. In an exploratory study, single doses of riociguat administered to patients with pulmonary arterial hypertension (PAH) treated with sildenafil showed additive hemodynamic effects. A higher rate of discontinuation, predominately due to hypotension, was observed in PAH patients treated with a combination of sildenafil and riociguat compared to those treated with sildenafil alone.

Concomitant use of LEVITRA with riociguat, a stimulator of sGC, is contraindicated (see **CONTRAINDICATIONS**).

**Alcohol:** The pharmacokinetics of LEVITRA were not influenced by alcohol, and the pharmacokinetics of alcohol were not influenced by co-administration with LEVITRA. No additive effects on blood pressure, heart rate, or bleeding time are seen when LEVITRA (20 mg) is administered with alcohol compared to placebo plus alcohol.

**Androgens, Pertinent Anti-androgens:** Vardenafil has not been studied in patients using androgen replacement therapy or anti-androgens.

**P-gp Substrate:** *In vitro* data suggest that effects of vardenafil on P-gp substrates more sensitive than digoxin, such as dabigatran, cannot be excluded.

### Drug-Drug Interactions

**Table 3: Established or Potential Drug-Drug Interactions**

<table>
<thead>
<tr>
<th>Proper Name</th>
<th>Ref</th>
<th>Effect</th>
<th>Clinical Comment</th>
</tr>
</thead>
<tbody>
<tr>
<td>Nitrates and nitric oxide donors</td>
<td>CT</td>
<td>Potentiates blood pressure lowering effects of sublingual nitrates taken 1 and 4 hours after a 20 mg dose of LEVITRA in healthy middle-aged subjects. These effects were not observed when 20 mg LEVITRA was taken 24 hours before the NTG.</td>
<td>Potentiation of the hypotensive effects of nitrates for patients with ischemic heart disease have not been evaluated, and concomitant use of nitrates with LEVITRA is contraindicated. (See CONTRAINDICATIONS.)</td>
</tr>
<tr>
<td>Potent CYP3A4 Inhibitors</td>
<td>CT/T</td>
<td>May decrease vardenafil clearance.</td>
<td>Concomitant use of LEVITRA with medicinal products containing cobicistat, HIV protease inhibitors such as indinavir, ritonavir, saquinavir, or atazanavir, and combinations of these, ketoconazole, and itraconazole is contraindicated, as they are potent inhibitors of CYP3A4. (See CONTRAINDICATIONS and DOSAGE AND ADMINISTRATION.)</td>
</tr>
</tbody>
</table>
### Table 3: Established or Potential Drug-Drug Interactions

<table>
<thead>
<tr>
<th>Proper Name</th>
<th>Ref</th>
<th>Effect</th>
<th>Clinical Comment</th>
</tr>
</thead>
<tbody>
<tr>
<td>Dabigatran etexilate</td>
<td>T</td>
<td>Comparison of digoxin and dabigatran as clinical probe substrates for P-gp showed that</td>
<td>In vitro data suggest that effects of vardenafil on P-gp substrates more sensitive than digoxin, such as dabigatran, cannot be excluded.</td>
</tr>
<tr>
<td></td>
<td></td>
<td>dabigatran is a more sensitive substrate for P-gp.</td>
<td></td>
</tr>
<tr>
<td>Erythromycin</td>
<td>CT</td>
<td>4-fold increase in vardenafil AUC and a 3-fold increase in C&lt;sub&gt;max&lt;/sub&gt; when 500 mg t.i.d.</td>
<td>A dose not exceeding 5 mg LEVITRA should be prescribed when used in combination with erythromycin. (See DOSAGE AND ADMINISTRATION.)</td>
</tr>
<tr>
<td></td>
<td></td>
<td>erythromycin was co-administered with vardenafil (5 mg) to healthy volunteers.</td>
<td></td>
</tr>
<tr>
<td>Clarithromycin</td>
<td>T</td>
<td>Expected to be similar to that for erythromycin.</td>
<td>A dose not exceeding 5 mg LEVITRA should be prescribed when used in combination with clarithromycin. (See DOSAGE AND ADMINISTRATION.)</td>
</tr>
<tr>
<td>Gatifloxacin</td>
<td>CT</td>
<td>An increase in QTcF (Fridericia) was observed when 10 mg vardenafil and 400 mg gatifloxacin</td>
<td>The clinical impact of these QT changes is unknown. Patients with congenital QT prolongation (long QT syndrome) and those taking Class IA (eg, quinidine,</td>
</tr>
<tr>
<td></td>
<td></td>
<td>were co-administered. The combined effect on QTcF appears to be small (Point Estimate of 4 msec with a 90% Confidence Interval of 1-6 msec) and additive</td>
<td>procainamide) or Class III (eg, amiodarone, sotalol) antiarrhythmic medications should avoid using LEVITRA. (See DETAILED PHARMACOLOGY.)</td>
</tr>
<tr>
<td></td>
<td></td>
<td>when compared to either drug alone.</td>
<td></td>
</tr>
<tr>
<td>Cimetidine</td>
<td>CT</td>
<td>No effect on AUC and C&lt;sub&gt;max&lt;/sub&gt; of vardenafil 20 mg when co-administered with 400 mg b.i.d.</td>
<td>Cimetidine, a non-specific CYP3A4 inhibitor, has no interaction with vardenafil.</td>
</tr>
<tr>
<td></td>
<td></td>
<td>cimetidine in healthy male volunteers.</td>
<td></td>
</tr>
<tr>
<td>Alpha-adrenergic</td>
<td>CT</td>
<td>Consistent with the vasodilatory effects of alpha-blockers and vardenafil, the concomitant</td>
<td>Concomitant treatment should only be initiated if the patient is stable on his alpha-blocker therapy. In these patients, LEVITRA should be initiated at the lowest</td>
</tr>
<tr>
<td>Receptor-blocking Agents</td>
<td></td>
<td>use of vardenafil with alpha-blockers may lead to symptomatic hypotension in some patients.</td>
<td>recommended starting dose of 5 mg. Vardenafil may be administered at any time with tamsulosin; with other alpha-adrenergic blocking agents a time separation of dosing should be considered.</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>In those patients already taking an optimized dose of vardenafil, alpha-blocker therapy should be initiated at the lowest dose. A stepwise increase in alpha-blocker dose may be associated with further lowering of blood pressure in patients taking a PDE5 inhibitor, including vardenafil. Patients should be advised that after stable concomitant therapy is established, vardenafil may be titrated as needed and tolerated. (See DETAILED PHARMACOLOGY, DOSAGE AND ADMINISTRATION)</td>
</tr>
<tr>
<td>Warfarin</td>
<td>CT</td>
<td>Warfarin, which is metabolized by CYP2C9, did not alter the plasma levels of LEVITRA when</td>
<td>No clinically relevant interactions.</td>
</tr>
<tr>
<td></td>
<td></td>
<td>co-administered. No effect on pharmacokinetic or pharmacodynamic activity of warfarin (25 mg)</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>when co-administered with LEVITRA (20 mg).</td>
<td></td>
</tr>
</tbody>
</table>
Table 3: Established or Potential Drug-Drug Interactions

<table>
<thead>
<tr>
<th>Proper Name</th>
<th>Ref</th>
<th>Effect</th>
<th>Clinical Comment</th>
</tr>
</thead>
<tbody>
<tr>
<td>Glyburide</td>
<td>CT</td>
<td>The AUC and C_{max} of glyburide was not altered, by co-administration of LEVITRA (20 mg). No evidence that LEVITRA pharmacokinetics were altered by co-administration of 3.5 mg o.d. glyburide, which is metabolized by CYP3A4.</td>
<td>No clinically relevant interactions.</td>
</tr>
<tr>
<td>Digoxin</td>
<td>CT</td>
<td>Digoxin (0.375 mg o.d.) did not alter the plasma levels of LEVITRA when taken in combination. The steady-state pharmacokinetics of digoxin was not altered by the co-administration of LEVITRA (20 mg).</td>
<td>No clinically relevant interactions.</td>
</tr>
<tr>
<td>Antacids (magnesium hydroxide/ aluminum hydroxide (MAALOX®))</td>
<td>CT</td>
<td>A single dose of MAALOX® did not affect the AUC or the C_{max} of LEVITRA.</td>
<td>No clinically relevant interactions.</td>
</tr>
<tr>
<td>H2 Antagonists Ranitidine</td>
<td>CT</td>
<td>The AUC and C_{max} of LEVITRA was not affected by co-administration of ranitidine (150 mg b.i.d.).</td>
<td>No clinically relevant interactions.</td>
</tr>
<tr>
<td>Acetylsalicylic Acid (ASA) ASPIRIN</td>
<td>CT</td>
<td>LEVITRA (10 and 20 mg) did not potentiate the increase in bleeding time caused by ASPIRIN (two 81 mg tablets o.d.).</td>
<td>No clinically relevant interactions.</td>
</tr>
<tr>
<td>Nifedipine</td>
<td>CT</td>
<td>LEVITRA (20 mg), when co-administered with slow-release nifedipine (30 mg or 60 mg once daily to hypertensive patients), did not affect the relative AUC or C_{max} of nifedipine, a drug that is metabolized via CYP3A4. LEVITRA (20 mg) produced mean additional blood pressure reductions of 5.9 mmHg and 5.2 mmHg for supine systolic and diastolic blood pressure, respectively, compared to placebo.</td>
<td>No clinically relevant interactions.</td>
</tr>
</tbody>
</table>

Legend: C=Case Study; CT=Clinical Trial; T=Theoretical

**Drug-Food Interactions**

Grapefruit juice, a weak inhibitor of CYP3A4 gut wall metabolism, may give rise to modest increases in plasma levels of LEVITRA. The combination should be avoided. A high-fat meal may delay t_{max} by one hour. (See ACTION AND CLINICAL PHARMACOLOGY.)

**Drug-Herb Interactions**

Interactions with herbal products have not been established.

**Drug-Laboratory Interactions**

Interactions with laboratory tests have not been established.
DOSAGE AND ADMINISTRATION

Dosing Considerations
LEVITRA (vardenafil tablets) can be taken with or without food. LEVITRA is not affected by moderate amounts of alcohol (0.5 g/kg body weight; approximately 3.4 fluid ounces of 40% alcohol in a 70 kg person). Sexual stimulation is required to achieve an erection.

Recommended Dose and Dosage Adjustment
The recommended starting dose of LEVITRA is 10 mg, taken orally 25 to 60 minutes before sexual activity. Sexual activity can be initiated as soon as 15 minutes and as long as 8-10 hours after taking LEVITRA. The dose may be increased to a maximum recommended dose of 20 mg or decreased to 5 mg based on efficacy and tolerability. (See CLINICAL TRIALS.) In patients with more severe erectile dysfunction (eg, diabetics) a more rapid titration may be appropriate. The recommended dose frequency is a maximum of once per day (as desired).

Geriatrics: A starting dose of 5 mg LEVITRA should be considered in patients 65 years or older. (See WARNINGS AND PRECAUTIONS, ACTION AND CLINICAL PHARMACOLOGY, and DETAILED PHARMACOLOGY.)

Hepatic Insufficiency: No dose adjustment for patients with mild hepatic impairment is required. Vardenafil clearance is reduced in patients with moderate hepatic impairment. In patients with moderate hepatic impairment, a 5 mg starting dose of LEVITRA is recommended, which may subsequently be increased to a maximum dose of 10 mg, based on tolerability and efficacy. (See WARNINGS AND PRECAUTIONS, ACTION AND CLINICAL PHARMACOLOGY, and DETAILED PHARMACOLOGY.) Vardenafil has not been evaluated in patients with severe hepatic impairment (Child-Pugh C).

Renal Insufficiency: No dose adjustment is required for patients with mild, moderate, or severe renal impairment. Vardenafil has not been evaluated in patients on dialysis.

OVERDOSAGE
For management of a suspected drug overdose, contact your regional Poison Control Centre.

LEVITRA (vardenafil tablets) in single doses up to 80 mg per day was tolerated in healthy male volunteers without producing serious adverse side effects. A 40 mg once daily dose of LÉVITRA demonstrated mild adverse events while 40 mg twice daily resulted in cases of severe back pain. No muscle or neurological toxicity was identified.

In cases of overdose, standard supportive measures should be taken as required. Renal dialysis is not expected to accelerate clearance because LEVITRA is highly bound to plasma proteins and is not significantly eliminated in the urine. For management of a suspected overdose please contact your regional Poison Control Centre.
TREATMENT OF PRIAPISM

Health professionals should warn patients that there have been rare reports of prolonged erections greater than 4 hours and priapism (painful erections greater than 6 hours in duration) for this class of compounds. In the event that an erection persists longer than 4 hours, the patient should seek immediate medical assistance. If priapism is not treated immediately, penile tissue damage and permanent loss of potency may result.

Detumescence Protocols

1. Aspirate 40 to 60 mL blood from either left or right corpora using a vacutainer and holder for drawing blood. Patient will often detumesce while blood is being aspirated. Apply ice for 20 minutes post aspiration if erection persists. If the first procedure is unsuccessful, try Procedure 2.

2. Put patient in supine position. Dilute 10 mg phenylephrine into 20 mL distilled water for injection (0.05%). With an insulin syringe, inject 0.1 to 0.2 mL (50-100 μg) into the corpora every 2 to 5 minutes until the detumescence occurs. The occasional patient may experience transient bradycardia and hypertension when given phenylephrine injections; therefore, monitor the patient's blood pressure and pulse every 10 minutes. Patients at risk include those with cardiac arrhythmias and diabetes. Refer to the prescribing information for phenylephrine before use. Do not give phenylephrine to patients on monoamine oxidase (MAO) inhibitors. When phenylephrine is used within the first 12 hours of erection, the majority of patients will respond. If Procedure 2 is unsuccessful, try Procedure 3.

3. If the above measures fail to detumesce the patient, a urologist should be consulted as soon as possible, especially if the erection has been present for many hours. If priapism is not treated immediately, penile tissue damage and / or permanent loss of potency may result.

ACTION AND CLINICAL PHARMACOLOGY

Mechanism of Action

LEVITRA (vardenafil tablets) is a highly selective cyclic GMP-specific phosphodiesterase type 5 (PDE5) inhibitor used for the treatment of male erectile dysfunction/difficulties.

Penile erection is a hemodynamic process initiated by the relaxation of smooth muscle in the corpus cavernosum and its associated arterioles. During sexual stimulation, nitric oxide is released from nerve endings and endothelial cells in the corpus cavernosum. Nitric oxide activates the soluble enzyme guanylate cyclase, resulting in increased synthesis of cyclic guanosine monophosphate (cGMP) in the corpus cavernosum smooth muscle cells. The cGMP in turn triggers smooth muscle relaxation, allowing increased blood flow into the penis and resulting in an erection. The tissue concentration of cGMP is regulated by both the rates of synthesis and degradation via phosphodiesterases (PDEs). The most prominent PDE in the human corpus cavernosum is the cGMP-specific phosphodiesterase type 5 (PDE5); by inhibiting PDE5, the enzyme responsible for cGMP degradation in the corpus cavernosum, vardenafil potently enhances the effect of endogenous nitric oxide, locally released in the corpus cavernosum upon sexual stimulation.
Studies on purified enzyme preparations have shown that vardenafil is a potent and selective inhibitor of human PDE5 with an IC\textsubscript{50} (concentration that inhibits 50% of enzyme activity) of 0.7 nM. The inhibitory effect of vardenafil is more potent on PDE5 than on other known phosphodiesterases (>15-fold relative to PDE6 [found in the retina], >130-fold relative to PDE1 [found in the brain, heart, and vascular system], >300-fold relative to PDE11 [found in the testes, penile vasculature, vascular smooth muscle, skeletal muscle, prostate, pituitary], and >1,000-fold relative to PDE2, 3, 4, 7, 8, 9, and 10). In vitro, vardenafil causes an elevation of cGMP in the isolated human corpus cavernosum, resulting in muscle relaxation. In the conscious rabbit, vardenafil causes a penile erection that is dependent upon endogenous nitric oxide synthesis and is potentiated by nitric oxide donors.

**Pharmacodynamics**

**Studies of LEVITRA on Erectile Response:** In patients with erectile dysfunction, erections considered sufficient for penetration (greater than or equal to 60% rigidity as measured by RIGISCAN® device [RigiScan Ambulatory Rigidity and Tumescence Monitor, Dacomed Corp., Minneapolis, USA]) occurred in 64% of men on 20 mg LEVITRA as early as 15 minutes post dosing compared to 52% of men on placebo. The overall erectile response of these subjects treated with LEVITRA became statistically significant compared to placebo at 25 minutes post dosing. In two separate double-blind, placebo-controlled crossover RIGISCAN® trials of men with erectile dysfunction of at least 6 months duration, 10 mg and 20 mg LEVITRA significantly improved erections initiated by visual sexual stimulation. Objective measurements of rigidity at the base and tip of the penis (by RIGISCAN®) during visual sexual stimulation showed significantly better results at all doses and time points with LEVITRA than with placebo. The mean duration of an erection, in response to visual sexual stimulation, sufficient for penetration was 54 and 67 minutes at the base and 39 and 45 minutes at the tip of the penis for the 10 mg and 20 mg doses of LEVITRA respectively, compared to 31 minutes at the base and 17 minutes at the tip for placebo.

The earliest elapsed time from dosing to attainment of an erection perceived to be sufficient for penetration and resulting in successful completion of intercourse was evaluated in a randomized, double-blind parallel group study in men with ED. The percentage of men reporting successful completion of intercourse after dosing with 10 mg or 20 mg vardenafil was greater than with placebo (p < 0.025) at all times ≥ 10 minutes and ≥ 11 minutes, respectively.

The amount of time from dosing (flexible dose) to attainment of an erection perceived to be sufficient for penetration and resulting in successful intercourse was evaluated in a randomized, double-blind, parallel group study in men with ED. The percentage of men reporting successful completion of intercourse 8 to 10 hours after dosing was greater with vardenafil compared to placebo (p < 0.001).

**Studies of LEVITRA on Blood Pressure and Heart Rate:** In a clinical pharmacology study of patients with erectile dysfunction, single doses of 20 mg LEVITRA caused a mean maximum decrease in supine blood pressure of 7 mmHg systolic and 8 mmHg diastolic (compared to placebo), accompanied by a mean maximum increase of heart rate of 4 beats per minute. The maximum decrease in blood pressure occurred between 1 and 4 hours after dosing. Following multiple dosing for 31 days, blood pressure responses were observed on Day 31 that were similar to those observed on Day 1. PDE5 inhibitors, including LEVITRA, may add to the blood pressure lowering effects of antihypertensive agents. (See **DRUG INTERACTIONS**.)
Larger effects were recorded among subjects receiving concomitant nitrates. (See CONTRAINDICATIONS and DETAILED PHARMACOLOGY.)

**Studies of LEVITRA on Cardiac Parameters:** PDE5 inhibitors, including LEVITRA, have been shown to increase the QT interval. In a study of the effect of vardenafil on the QT interval in 59 healthy males, therapeutic and supratherapeutic doses of vardenafil and another member of the PDE5 inhibitor class produced minimal increases in the QTc interval. This effect on the QT interval is consistent with that observed with other members of the PDE5 inhibitor class. In a post-marketing study evaluating the effect of combining LEVITRA with another drug of comparable QT effect (400 mg gatifloxacin), it was shown that the drug combination produced an additive QT effect when compared with either drug alone. (See WARNINGS AND PRECAUTIONS, DRUG INTERACTIONS, and DETAILED PHARMACOLOGY.)

**Studies of LEVITRA on Exercise Performance in Patients with Coronary Artery Disease (CAD):** In two independent trials that assessed 10 mg (N=41) and 20 mg (N=39) LEVITRA respectively, LEVITRA did not alter the total treadmill exercise time compared to placebo. The patient population included men aged 40-80 years with stable exercise-induced angina documented by at least one of the following: 1) prior history of MI, CABG, PTCA, or stenting (not within 6 months); 2) positive coronary angiogram showing at least 60% narrowing of the diameter of at least one major coronary artery; or 3) a positive stress echocardiogram or stress nuclear perfusion. The results of the 20 mg study are shown in Table 4.

<table>
<thead>
<tr>
<th>Parameter</th>
<th>20 mg LEVITRA (Mean in Seconds)</th>
<th>Placebo (Mean in Seconds)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Treadmill Exercise Time</td>
<td>414 ± 114 (N=36)</td>
<td>411 ± 124 (N=36)</td>
</tr>
<tr>
<td>Total Time to Develop Symptoms of Angina Pectoris (first awareness)</td>
<td>354 ± 137 (N=36)</td>
<td>347 ± 143 (N=36)</td>
</tr>
<tr>
<td>Total Time to ST-Segment depression (1 mm or greater change from baseline)</td>
<td>364 ± 101 (N=35)</td>
<td>366 ± 105 (N=36)</td>
</tr>
</tbody>
</table>

**Studies of LEVITRA on Vision:** Single oral doses of phosphodiesterase inhibitors have demonstrated transient dose-related impairment of colour discrimination (blue/green) using the Farnsworth-Munsell 100-hue test and reductions in electroretinogram (ERG) b-wave amplitudes, with peak effects near the time of peak plasma levels. These findings are consistent with the inhibition of PDE6 in rods and cones, which is involved in phototransduction in the retina. The findings were most evident one hour after administration, diminishing but still present 6 hours after administration. In a single dose study in 25 normal males, 40 mg LEVITRA, twice the maximum daily recommended dose, did not alter visual acuity, intraocular pressure, fundoscopic and slit lamp findings. (See DETAILED PHARMACOLOGY.)

**Studies of LEVITRA on Sperm Characteristics:** In healthy male volunteers, there was no effect on sperm motility, morphology, or a variety of other parameters relevant to male reproductive function 1.5 hours after single 20 mg oral doses of LEVITRA were administered.

In a 6-month placebo-controlled study conducted with healthy males or males with erectile dysfunction, aged 25-64 years, daily treatment with 20 mg vardenafil had no effect on sperm
concentration, count, motility, or morphology. In addition, vardenafil had no effect on serum levels of testosterone, luteinizing hormone, or follicle-stimulating hormone. The effect of vardenafil on human fertility was not directly evaluated in this study. Although daily treatment with vardenafil 20 mg for six months in this study did not demonstrate significant effects on sperm characteristics, the effect of longer duration of treatment with vardenafil on sperm characteristics is unknown.

**Pharmacokinetics**

Table 5: Summary of Vardenafil Pharmacokinetic Parameters in Healthy Male Volunteers

<table>
<thead>
<tr>
<th></th>
<th>( C_{max} )</th>
<th>( t^{1/2} ) (h)</th>
<th>AUC (_{0-\infty})</th>
<th>Clearance</th>
<th>Volume of distribution</th>
</tr>
</thead>
<tbody>
<tr>
<td>Single 20 mg dose (mean)</td>
<td>15-17 μg*L/h</td>
<td>4-5 h</td>
<td>70 μg*h/L</td>
<td>56 L/h</td>
<td>208 L</td>
</tr>
</tbody>
</table>

LEVITRA (vardenafil tablets) is rapidly absorbed after oral administration, with a mean absolute bioavailability of about 15%. Its pharmacokinetics approximate dose-proportionality over the recommended dose range (5 mg, 10 mg, and 20 mg). Vardenafil is eliminated predominantly by hepatic metabolism. The elimination half-life is approximately 4-5 hours. Mean vardenafil plasma concentrations measured over 24 hours after the administration of a single oral dose of 20 mg vardenafil to healthy male volunteers are shown in Figure 1.

**Figure 1: Mean Plasma Concentration Curve for 20 mg Vardenafil after Oral Administration**

Absorption: Vardenafil is rapidly absorbed, with maximum observed plasma concentrations detected as early as 15 minutes post administration. In the fasted state, maximum plasma concentrations are achieved between 30 to 120 minutes (median 60 minutes) 90% of the time after oral dosing of vardenafil.

When LEVITRA is taken with a typical meal comprised of 30% fat, the rate and extent of absorption of vardenafil are unchanged compared to administration under fasting conditions. Consumption of a
high-fat meal caused a reduction in $C_{\text{max}}$ of 18-50% without change in AUC (Area Under the Curve); $t_{\text{max}}$ was delayed by one hour.

Absorption levels are unchanged with a moderate amount of alcohol.

**Distribution:** The mean steady-state volume of distribution ($V_{ss}$) for vardenafil is 208 L, indicating extensive tissue distribution. Vardenafil and its major metabolite, M-1, are highly bound to plasma proteins (about 95% for parent drug and M-1). This protein binding is reversible and independent of total drug concentrations.

Ninety minutes after administration of a single dose of 20 mg LEVITRA, less than 0.0002% of the administered dose is detected in the semen. The concentrations of vardenafil and its primary metabolite in the ejaculate 1.5 hours post dose were 49% and 71%, respectively, of the concentrations in plasma at the same time point.

**Metabolism:** Vardenafil is eliminated predominantly by hepatic metabolism via cytochrome P450 (CYP) 3A4, with some contribution from the CYP3A5 and CYP2C isoforms. The major circulating metabolite, M-1, results from desethylation at the piperazine moiety of vardenafil. M-1 is subject to further metabolism. The plasma concentration of M-1 is approximately 26% of the parent compound. This metabolite shows a phosphodiesterase selectivity profile similar to that of vardenafil and an in vitro inhibitory potency for PDE5 of 28% compared to vardenafil. Therefore, M-1 accounts for approximately 7% of the total pharmacologic activity.

**Excretion:** The total body clearance of vardenafil is 56 L/h and the terminal half-life is approximately 4-5 hours. After oral administration, vardenafil is excreted as metabolites predominantly in the feces (approximately 91-95% of administered oral dose) and to a lesser extent in the urine (approximately 2-6% of administered oral dose).

**Special Populations and Conditions**

**Pediatrics (< 18 years of age):** Vardenafil has not been evaluated in individuals less than 18 years old.

**Geriatrics (≥ 65 years of age):** A starting dose of 5 mg LEVITRA should be considered in patients 65 years and older. On average, elderly males (65 years and over) had a 52% higher vardenafil AUC and a 34% higher maximum concentration ($C_{\text{max}}$) than younger males (18-45 years); however, this difference was not statistically significant. (See **WARNINGS AND PRECAUTIONS, DOSAGE AND ADMINISTRATION**, and **DETAILED PHARMACOLOGY**.)

**Hepatic Insufficiency:** No dose adjustment is required in patients with mild hepatic impairment. In patients with mild hepatic impairment (Child-Pugh A), the vardenafil AUC was increased 17% and the $C_{\text{max}}$ was increased 22%, compared to healthy male volunteers, following a 10 mg vardenafil dose. In patients with moderate impairment (Child-Pugh B), the vardenafil AUC was increased 160% and $C_{\text{max}}$ was increased 133%, compared to healthy male volunteers, following a 10 mg vardenafil dose.

In patients with moderate hepatic impairment, a 5 mg starting dose of LEVITRA is recommended, which may subsequently be increased to a maximum dose of 10 mg, based on tolerability and efficacy. (See **WARNINGS AND PRECAUTIONS, DOSAGE AND ADMINISTRATION**, and...
DETAILED PHARMACOLOGY. Vardenafil has not been evaluated in patients with severe hepatic impairment (Child-Pugh C).

Renal Insufficiency: No dose adjustment is required in patients with renal impairment. In patients with mild (creatinine clearance \( \text{CL}_{\text{cr}} \geq 50-80\, \text{mL/min} \)), moderate \( \text{CL}_{\text{cr}} > 30-50\, \text{mL/min} \), or severe \( \text{CL}_{\text{cr}} \leq 30\, \text{mL/min} \) renal impairment, the pharmacokinetics of vardenafil were similar to that of a control group with normal renal function. Vardenafil pharmacokinetics have not been evaluated in patients requiring dialysis.

STORAGE AND STABILITY

Store between 15-30°C. Do not freeze.

DOSAGE FORMS, COMPOSITION AND PACKAGING

LEVITRA (vardenafil tablets) is available as orange, film coated round tablets marked with “BAYER” cross on one side and “5”, “10”, or “20” on the other side equivalent to 5 mg, 10 mg, and 20 mg of vardenafil, respectively.

Table 6: Availability of LEVITRA

<table>
<thead>
<tr>
<th>Package</th>
<th>Strength</th>
</tr>
</thead>
<tbody>
<tr>
<td>Blister package of 4</td>
<td>5 mg</td>
</tr>
<tr>
<td></td>
<td>10 mg</td>
</tr>
<tr>
<td></td>
<td>20 mg</td>
</tr>
</tbody>
</table>

Composition: LEVITRA tablets contain vardenafil hydrochloride equivalent to 5 mg, 10 mg, or 20 mg of vardenafil per tablet for oral administration. The tablets also contain the following non-medicinal ingredients: microcrystalline cellulose, crospovidone, anhydrous colloidal silica, magnesium stearate, hydroxypropyl methylcellulose, polyethylene glycol, titanium dioxide, yellow ferric oxide, and red ferric oxide.
PART II: SCIENTIFIC INFORMATION

PHARMACEUTICAL INFORMATION

Drug Substance

Proper name: Vardenafil hydrochloride
Chemical name: 2-[2-Ethoxy-5-(4-ethyl-piperazine-1-sulfonyl)-phenyl]-5-methyl-7-propyl-3H-imidazo[5,1-f][1,2,4]triazin-4-one monohydrochloride trihydrate
Molecular formula: C_{23}H_{32}N_{6}O_{4}S X HCl X 3H_{2}O
Structural formula:

\[
\begin{align*}
\text{Molecular weight:} & \quad 579.1 \text{ g/mole} \\
\text{Physicochemical properties:} & \quad \text{Vardenafil hydrochloride is a nearly colourless, crystalline substance} \\
\text{pK}_a: & \quad \text{Protonation of the ethylpiperazin nitrogen} \quad 6.7 \\
& \quad \text{Deprotonation of the amide proton} \quad 8.8 \\
\text{Partition coefficient:} & \quad \log P_{o/w} = 0.0 \text{ (octanol/water)} \\
& \quad \log P_{o/w} = 3.2 \text{ (octanol/phosphate buffer, pH = 7)} \\
\text{Solubility:} & \quad \text{Water} \quad 0.11 \text{ mg/mL} \\
& \quad 0.1 \text{ N HCl} \quad 65 \text{ mg/mL} \\
& \quad 0.1 \text{ M NaOH} \quad 5.9 \text{ mg/mL} 
\end{align*}
\]

CLINICAL TRIALS

LEVITRA (vardenafil tablets) demonstrated clinically meaningful and statistically significant improvement of erectile function compared to placebo in all major efficacy trials including studies in special populations (men with diabetes, men with radical prostatectomy, men with spinal cord injury).
Study Demographics and Trial Design

LEVITRA was evaluated primarily at doses of 5 mg, 10 mg, and 20 mg in four major placebo-controlled, multicenter trials for men with erectile dysfunction. Two trials were conducted in the general population, and two trials were conducted in special populations (diabetes mellitus and post-prostatectomy patients). Across all trials, LEVITRA was taken as needed by over 3690 men, aged 18 to 89 years, with erectile dysfunction. Many of the men participating in the trial had other medical conditions. Of the 3690 men, over 1450 were treated with LEVITRA for 6 months or longer.

Of the total of 3402 patients treated in Phase III clinical trials with LEVITRA, 748 (22%) were 65 years and older.

Patients were required to have a history of erectile dysfunction (defined as a consistent change in the quality of erection that adversely affected the patient's satisfaction with sexual intercourse) of at least 6 months. More than half of the patients reported ED of more than 2 years in duration. Patients had a clinical diagnosis of ED, as assessed by the clinical investigator. See WARNINGS AND PRECAUTIONS, for patients with specific cardiovascular disease who were not included in the clinical trials. In addition, patients with significant renal and hepatic insufficiency and retinitis pigmentosa were excluded from the pivotal studies. Patients on certain medications such as androgens, anti-androgens, and trazodone were excluded from the clinical trials. In the pivotal clinical trials, patients were instructed to take no more than one dose of LEVITRA per day without restriction to intake of food.

The efficacy of LEVITRA was assessed by patient diaries completed shortly after dosing and by questionnaires completed in the doctor's office. Several assessment tools were used to evaluate the effect of LEVITRA on erectile function, including the International Index of Erectile Function (IIEF), Sexual Encounter Profile (SEP) and Global Assessment Question (GAQ). The primary endpoints of these studies included the Erectile Function Domain of the IIEF, and SEP Questions 2 and 3 (SEP 2, SEP 3).

The IIEF is a recall questionnaire that was administered at the end of a treatment-free baseline period and subsequently at follow-up visits after randomization. The severity categories used in the studies of LEVITRA were assigned based on an aggregated modification of the Cappelleri scale, ie, no ED (26-30), mild ED (17-25), moderate ED (11-16), and severe ED (1-10). (See REFERENCES.)

The Sexual Encounter Profile (SEP) is a diary in which patients recorded each sexual attempt made through a study. SEP 2 asked, "Were you able to insert your penis into your partner's vagina?" SEP 3 asked, "Did your erection last long enough for you to have successful intercourse?"
The secondary outcome measures assessed the patient's satisfaction with sexual intercourse and his satisfaction with his overall sex life/relationship. The measures included the GAQ and SEP 4 and 5. The GAQ asked, "Has the treatment you have been taking during the last four weeks improved your erections?" SEP 4 asked, "Were you satisfied with the hardness of your erection?" SEP 5 asked "Were you satisfied overall with this sexual experience?"

Supportive evidence was generated in RIGISCAN® studies. (See ACTION AND CLINICAL PHARMACOLOGY: Pharmacodynamics.)

LEVITRA was also evaluated in a randomized, double-blind, placebo-controlled, multicentre trial in subjects with ED solely secondary to traumatic spinal cord injury. 396 men (197 – vardenafil and 199 – placebo), with a mean age of 40 (18-80), were valid for Intent-to-Treat analysis in this 12-week flexible-dose (5 mg, 10 mg, 20 mg vardenafil) trial.

**Efficacy of LEVITRA in the Erectile Dysfunction Population**

Table 7: Trials

<table>
<thead>
<tr>
<th>Study No.</th>
<th>Trial Design</th>
<th>Dosage, Route of Administration and Duration</th>
<th>Study Subjects (N=Patients Valid for Intent-to-treat Analysis)</th>
<th>Mean Age (Range) in yrs</th>
<th>Gender</th>
</tr>
</thead>
<tbody>
<tr>
<td>100249</td>
<td>Randomized, double-blind, placebo-controlled, multicentre, fixed-dose trial (North America)</td>
<td>5 mg, 10 mg, 20 mg LEVITRA and placebo, oral, as needed, no more than once daily, for 6 months</td>
<td>Placebo: N=177 5 mg: N=190 10 mg: N=196 20 mg: N=186</td>
<td>57 (20-83)</td>
<td>Males</td>
</tr>
<tr>
<td>10128</td>
<td>Randomized, double-blind, placebo-controlled, multicentre, fixed dose trial (Europe)</td>
<td>5 mg, 10 mg, 20 mg LEVITRA and placebo, oral, as needed, no more than once daily, for 3 months</td>
<td>Placebo: N=160 5 mg: N=156 10 mg: N=157 20 mg: N=163 Sildenafil 50 mg: N=162</td>
<td>55 (21-81)</td>
<td>Males</td>
</tr>
<tr>
<td>100250 (diabetes mellitus)</td>
<td>Prospective, randomized, double-blind, placebo-controlled, multicentre, fixed dose trial</td>
<td>10 mg, 20 mg LEVITRA and placebo, oral, as needed, no more than once daily, for 3 months</td>
<td>Placebo: N=140 10 mg: N=149 20 mg: N=141</td>
<td>57 (33-81)</td>
<td>Males</td>
</tr>
<tr>
<td>100285 (post-prostatectomy)</td>
<td>Prospective, randomized, double-blind, placebo-controlled, multicentre, fixed dose trial</td>
<td>10 mg, 20 mg LEVITRA and placebo, oral, as needed, no more than once daily, for 3 months</td>
<td>Placebo: N=137 10 mg: N=139 20 mg: N=147</td>
<td>60 (44-77)</td>
<td>Males</td>
</tr>
<tr>
<td>10473 (spinal cord injury)</td>
<td>Randomized, double-blind, placebo-controlled, multicentre, parallel-group, flexible dose trial</td>
<td>Starting dose of 10 mg LEVITRA and placebo, subjects could be up (20 mg) or down (5 mg) titrated at 4 weeks and up or down titrated again at 8 weeks, oral, for 12 weeks.</td>
<td>Placebo: N=199 5 mg, 10 mg, 20 mg Vardenafil: N=197</td>
<td>40 (18-80)</td>
<td>Males</td>
</tr>
</tbody>
</table>
Table 7: Trials

| 100493 (duration of action) | Randomized, double-blind, placebo-controlled, multicentre, parallel-group, flexible dose trial | Starting dose of 10 mg LEVITRA and placebo, subjects could be up (20 mg) or down (5 mg) titrated after 2 weeks for the following 4 weeks, and up or down titrated at 6 weeks. | Placebo: N=159 Vardenafil: N=177 | 56 (28-79) | Males |

a based on patients valid for safety analysis

Study Results

Table 8: Results of Study 100249 in the General Erectile Dysfunction Population

<table>
<thead>
<tr>
<th>Primary Endpoints</th>
<th>Associated value and statistical significance for LEVITRA at 5 mg, 10 mg and 20 mg</th>
<th>Associated value for Placebo</th>
</tr>
</thead>
</table>
| Erectile Domain Mean Score | 5 mg: 17.5^{a,b} (p < 0.0001)  
10 mg: 22^{a,b} (p < 0.0001)  
20 mg: 22^{a,b} (p < 0.0001) | Placebo: 15^{a,b} |
| SEP 2 (Successful Penetration) (%) | 5 mg: 65^{a}, 66^{b} (p < 0.0001)  
10 mg: 75^{a}, 76^{b} (p < 0.0001)  
20 mg: 80^{a}, 81^{b} (p < 0.0001) | Placebo: 52^{a,b} |
| SEP 3 (Successful Intercourse) (%) | 5 mg: 52^{a}, 52^{b} (p < 0.0001)  
10 mg: 65^{a,b} (p < 0.0001)  
20 mg: 65^{a}, 67^{b} (p < 0.0001) | Placebo: 32^{a}, 33^{b} |
| GAQ (Improved Erections) (%) | 5 mg: 65^{b} (p < 0.0001)  
10 mg: 80^{b} (p < 0.0001)  
20 mg: 85^{b} (p < 0.0001) | Placebo: 28^{b} |

a At 3 months  
b At 6 months

Erectile Function Domain

Two pivotal trials were conducted in ED patients, a six-month trial in North America and a three-month study in Europe. In the efficacy trials conducted in the general ED population, LEVITRA showed clinically meaningful and statistically significant improvement in the Erectile Function (EF) Domain score compared to placebo. Mean baseline EF Domain score in these trials was 11.8. An EF Domain score of ≤ 10 reflects severe disease, 11-16 moderate, 17-21 mild to moderate, 22-25 mild, and 26-30 normal erectile function. The EF Domain scores, in response to treatment, as seen in the pivotal six month study are presented in Figure 2.
SEP 2 (Successful Penetration)

In the 6-month study, LEVITRA significantly improved the rates of achieving an erection sufficient for penetration (SEP 2) with 5 mg, 10 mg, and 20 mg compared to placebo. (See Figure 3.) The 3 month study confirmed these results at all time points.

Figure 3: Improvements in Rates of Successful Penetration (SEP 2)*

Mean per patient success rate; *p < 0.0001 vs placebo, valid for ITT; overall success as defined by percentage of successful attempts at penetration from first dose to last dose over the treatment period.

SEP 2: Were you able to insert your penis into your partner’s vagina?
**SEP 3 (Successful Intercourse)**

LEVITRA demonstrated a clinically meaningful and statistically significant increase in the overall rate of maintenance of erection to successful intercourse (SEP 3) with 5 mg, 10 mg and 20 mg responses at 51%, 65% and 65% respectively compared to 32% response in the placebo group at 3 months in the 6-month pivotal trial. This efficacy was seen at all time points up to 6 months, suggesting that vardenafil's effect is maintained over time. The 3-month pivotal trial also showed comparable efficacy. (See Figure 4.)

**Figure 4: Improvements in Rates of Maintenance of Erection to Successful Intercourse (SEP 3)**

\* p < 0.0001 vs. placebo

a SEP 3: Did your erection last long enough for you to have successful intercourse?

**GAQ (Improved Erections)**

LEVITRA improved erections in 65%, 80%, and 85% of the patients on 5 mg, 10 mg, and 20 mg respectively, at 6 months compared to 28% on placebo in 507 patients in the 6-month randomized, double-blind, fixed-dose trial. (See Figure 5.)
Figure 5: Percentage of Improved Erections (GAQ)^

<table>
<thead>
<tr>
<th>Treatment Groups</th>
<th>Placebo (n=91)</th>
<th>LEVITRA® 5 mg (n=128)</th>
<th>LEVITRA® 10 mg (n=148)</th>
<th>LEVITRA® 20 mg (n=140)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Patients Reporting Improvements</td>
<td>28 %</td>
<td>* 65 %</td>
<td>* 80 %</td>
<td>* 85 %</td>
</tr>
<tr>
<td>Placebo (n=91)</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>LEVITRA® 5 mg (n=128)</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>LEVITRA® 10 mg (n=148)</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>LEVITRA® 20 mg (n=140)</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

*p<0.0001 vs placebo; valid for intent to treat (ITT) population; patients completing 6 months.

a GAQ: Has the treatment you have been taking during the last 4 weeks improved your erections?

**Patient Confidence and Sexual Satisfaction**

The IIEF also measures patients' confidence that they can attain and keep an erection sufficient for sexual intercourse (IIEF Question 15). LEVITRA statistically significantly improved patient confidence.

LEVITRA also improved sexual function domain scores for Intercourse Satisfaction, Orgasmic Function, and Overall Satisfaction as compared to placebo in the major efficacy trials in the general ED population, as assessed by the IIEF Questionnaire. (See Table 9.)

**Table 9: Summary of IIEF Domain Scores in LEVITRA 6-Month Trial**

<table>
<thead>
<tr>
<th>IIEF Domain</th>
<th>Maximum Domain Scores</th>
<th>LEVITRA 20 mg Mean Value at Baseline</th>
<th>Mean Value at Endpoint</th>
<th>Mean Scores, Untreated Men without ED</th>
</tr>
</thead>
<tbody>
<tr>
<td>Intercourse Satisfaction</td>
<td>15</td>
<td>6.8</td>
<td>9.8</td>
<td>10.6</td>
</tr>
<tr>
<td>Orgasmic Function</td>
<td>10</td>
<td>7</td>
<td>6.7</td>
<td>8.8</td>
</tr>
<tr>
<td>Overall Satisfaction</td>
<td>10</td>
<td>4.5</td>
<td>7</td>
<td>8.6</td>
</tr>
</tbody>
</table>

Patients on LEVITRA also reported a greater satisfaction with the quality of their erection. Eighteen, 38, 52 and 59% of patients reported satisfaction with the hardness of their erection on placebo, 5 mg, 10 mg, and 20 mg LEVITRA, respectively.
Reliability

The ability of LEVITRA to provide reliable efficacy over time was examined in this study. The results show that for "successful penetration (SEP 2)" the first attempt success rate → subsequent success rates up to 12 weeks were 74% → 91% and 46% → 77% for 20 mg LEVITRA and placebo, respectively. Similarly, for "successful intercourse (SEP 3)" the first attempt success rate → subsequent success rates up to 12 weeks were 61% → 85% and 29% → 57% for 20 mg LEVITRA and placebo, respectively.

The efficacy of LEVITRA with regard to EF Domain and SEP 3 responses was maintained in patients treated for one year with 10 or 20 mg doses. The incidence of successful intercourse, which was approximately 15% at baseline, increased markedly for both dosing groups beginning with the first post baseline assessment at Week 4. At the end of the one year treatment period, the incidence of successful intercourse was 82% in the 10 mg LEVITRA group and 86% in the 20 mg LEVITRA group. The efficacy of LEVITRA was maintained in patients treated for one year with 10 or 20 mg doses.

Trials in Patients Non-responsive to Sildenafil

Men who had a history of failure to respond to sildenafil were included in the 3-month pivotal trial. Marked differences were seen in patients with a history of failure to respond to sildenafil. Despite the fact that a proportion of these patients derived benefit from repeated treatment with sildenafil, the improvements in erectile function, penetration and maintenance of erection were greater with vardenafil. This suggests that a proportion of patients who fail to respond to sildenafil would improve if given LEVITRA.

Patients completing this trial, after a 30-day drug-free period, were subsequently administered 10 mg LEVITRA for 4 weeks, and then offered an optional titration regimen of LEVITRA. Seventy percent of patients elected to receive 20 mg LEVITRA and this dose was associated with a mean increase of erectile function domain score of 4.1 compared to an increase of 0.2 points in patients who continued treatment with 10 mg LEVITRA.

Flexible-dose Trials in General Erectile Dysfunction Population

In another study with flexible LEVITRA dosing, 367 men in the broad population were offered to titrate up or down from the initial 10 mg LEVITRA dose over a 3-month treatment period. For those preferring a 20 mg dose (72% of men), a mean increase in erectile function domain score of 4.6 points was seen (baseline: 18.0 ± 7.0; endpoint: 22.6 ± 6.2), compared to an increase in 0.6 points in the placebo group (baseline: 13.0 ± 5.8; endpoint: 13.6 ± 6.8). The rate of discontinuation due to adverse events was similar to placebo.

Efficacy of LEVITRA in Diabetes Mellitus Patients

In patients with Type 1 or Type 2 diabetes mellitus, LEVITRA demonstrated clinically meaningful and statistically significant improvement in erectile function in a 3-month prospective fixed dose, double-blind, placebo-controlled trial. Significant improvements were shown in the EF Domain score (the rates of obtaining an erection sufficient for penetration and successful intercourse), and hardness compared to placebo for the test doses of 10 mg and 20 mg LEVITRA at all time points during three months of treatment. (See Table 10.)
Table 10: Summary of Efficacy Variables in LEVITRA Diabetes Mellitus Trials

<table>
<thead>
<tr>
<th>Efficacy Variable</th>
<th>Placebo (N=138)</th>
<th>LEVITRA 10 mg (N=145)</th>
<th>LEVITRA 20 mg (N=139)</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Endpoint</td>
<td>Change</td>
<td>Endpoint</td>
</tr>
<tr>
<td>IIEF, LS Mean</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Erectile Function Domain Score</td>
<td>12.6</td>
<td>1.4</td>
<td>17.1</td>
</tr>
<tr>
<td>Overall Satisfaction Domain Score</td>
<td>4.8</td>
<td>0.4</td>
<td>6.3</td>
</tr>
<tr>
<td>Intercourse Satisfaction Domain Score</td>
<td>6.6</td>
<td>0.6</td>
<td>8.4</td>
</tr>
<tr>
<td>SEP Diary, % ‘Yes’ Response</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Question 2 (Vaginal Penetration)</td>
<td>36</td>
<td>3</td>
<td>61</td>
</tr>
<tr>
<td>Question 3 (Successful Intercourse)</td>
<td>23</td>
<td>12</td>
<td>49.2</td>
</tr>
</tbody>
</table>

* p =0.0001

Analysis of the efficacy data showed that the degree of glycemic control did not affect the response to vardenafil, as shown in Table 11.

Table 11: EF Domain Scores (With Change from Baseline) and GAQ of Patients in Study 100250 in the Different Subgroups of Glycemic Control at Week 12 (LOCF, ITT Population)

<table>
<thead>
<tr>
<th>EF Domain</th>
<th>Placebo</th>
<th>LEVITRA 10 mg</th>
<th>LEVITRA 20 mg</th>
<th>Placebo</th>
<th>LEVITRA 10 mg</th>
<th>LEVITRA 20 mg</th>
</tr>
</thead>
<tbody>
<tr>
<td>HbA1c #7%: Optimal</td>
<td>11.4 (0.0)</td>
<td>20.4 (9.3)</td>
<td>21.6 (7.9)</td>
<td>10.3</td>
<td>67.6</td>
<td>67.7</td>
</tr>
<tr>
<td>HbA1c 7%-%8.4%: Sub-optimal</td>
<td>11.4 (1.1)</td>
<td>14.4 (3.6)</td>
<td>18.9 (6.8)</td>
<td>15.6</td>
<td>45.6</td>
<td>67.4</td>
</tr>
<tr>
<td>HbA1c 8.4%-#12%: Inadequate</td>
<td>12.3 (1.2)</td>
<td>15.6 (4.8)</td>
<td>19.0 (8.1)</td>
<td>16.9</td>
<td>51.1</td>
<td>70.4</td>
</tr>
</tbody>
</table>

In this population, which is typically more resistant to therapy, response rates for improvement of erection were 57% with 10 mg, and 72% with 20 mg LEVITRA compared to 13% with placebo for patients who completed three months of the trial as measured by GAQ. (See Figure 6.) Patients in the active treatment group continued on blinded active therapy of LEVITRA for a total of 6 months. These patients demonstrated response rates of 61% and 73% for 10 mg and 20 mg LEVITRA, respectively, again suggesting that vardenafil's effect is maintained over time.
**Efficacy of LEVITRA in Post-prostatectomy Patients**

In a 3-month prospective multicenter, fixed-dose, double-blind, placebo-controlled trial in post-prostatectomy patients, LEVITRA demonstrated significant improvements in erectile function. EF Domain score (the rates of obtaining an erection sufficient for penetration and successful intercourse) and hardness were significantly improved compared to placebo for the tested doses of 10 mg and 20 mg LEVITRA at all time points.

### Table 12: Summary of Efficacy Variables in LEVITRA Post-prostatectomy Trial

<table>
<thead>
<tr>
<th>Efficacy Variable</th>
<th>Placebo (N=140)</th>
<th>LEVITRA 10 mg (N=140)</th>
<th>LEVITRA 20 mg (N=147)</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Endpoint</strong></td>
<td><strong>Change</strong></td>
<td><strong>Endpoint</strong></td>
<td><strong>Change</strong></td>
</tr>
<tr>
<td>IIEF, Mean</td>
<td>9.2</td>
<td>0.1</td>
<td>15.3</td>
</tr>
<tr>
<td>Erectile Function Domain Score</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Overall Satisfaction Domain Score</td>
<td>4.9</td>
<td>0.1</td>
<td>6.4</td>
</tr>
<tr>
<td>Intercourse Satisfaction Domain Score</td>
<td>5.2</td>
<td>0.1</td>
<td>7.7</td>
</tr>
<tr>
<td><strong>SEP Diary, % ‘Yes’ Response</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Question 2 (Vaginal Penetration)</td>
<td>21.8</td>
<td>6.6</td>
<td>46.6</td>
</tr>
<tr>
<td>Question 3 (Successful Intercourse)</td>
<td>9.9</td>
<td>3.3</td>
<td>37.2</td>
</tr>
</tbody>
</table>

* p=0.001

Improved erectile function response rates as based on GAQ was 59% on 10 mg, and 65% on 20 mg vardenafil compared to 13% on placebo at 3 months. In the subgroup of patients with bilateral nerve-sparing prostatectomy (N=236), the response rate to the GAQ in patients who completed 3 months of treatment was 60% for 10 mg, and 71% for 20 mg LEVITRA, compared to 12% for placebo. The Depression Domain of the Duke Health Profile was significantly improved in the 20 mg LEVITRA treatment arm compared to placebo. In patients with depressive symptoms, as measured by a score of 16 or higher on the Center for Epidemiologic Studies-Depression Scale (CES-D), 20 mg LEVITRA was associated with improvement in reported depressive symptoms.
Figure 7 shows the effect of placebo and 20 mg LEVITRA on Erectile Function Domain Score and SEP 3 by severity of ED at baseline in post-prostatectomy patients.

Figure 7: EF Domain Scores of IIEF (A) and Percent Successful Intercourse (B) According to Baseline Severity in Prostatectomy Patients

**Efficacy of LEVITRA in Patients with Spinal Cord Injury**

In a flexible-dose clinical trial in patients with Spinal Cord Injury, vardenafil significantly improved the erectile function domain score, the ability to obtain and maintain an erection long enough for successful intercourse and penile rigidity compared to placebo. The number of patients who returned to a normal IIEF domain score (≥26) after 12 weeks of treatment were 52% on vardenafil compared to 9% on placebo. The response rates for the ability to obtain and maintain an erection were 76% and 59% on vardenafil compared to 41% and 22% on placebo for patients who completed three months treatment. Both measurements were clinically and statistically significant (p<0.001).

---

a Values are %
In this population, response rates for improvement of erection were 83% with LEVITRA compared to 26% with placebo for patients who completed three months of the trial as measured by GAQ (See Figure 8).

**Figure 8: Percentage of Patients Reporting an Improvement in Erections in the Spinal Cord Injury Trial**

<table>
<thead>
<tr>
<th></th>
<th>Vardenafil</th>
<th>Placebo</th>
</tr>
</thead>
<tbody>
<tr>
<td>Weeks 0-4</td>
<td>72*</td>
<td>17</td>
</tr>
<tr>
<td>n=189</td>
<td>n=193</td>
<td></td>
</tr>
<tr>
<td>Weeks 4-8</td>
<td>82</td>
<td>25</td>
</tr>
<tr>
<td>n=164</td>
<td>n=175</td>
<td></td>
</tr>
<tr>
<td>Weeks 8-12</td>
<td>83*</td>
<td>26</td>
</tr>
<tr>
<td>n=184</td>
<td>n=174</td>
<td></td>
</tr>
<tr>
<td>LOCF</td>
<td>80*</td>
<td>26</td>
</tr>
<tr>
<td>n=198</td>
<td>n=196</td>
<td></td>
</tr>
</tbody>
</table>

**Efficacy of LEVITRA 8±2 Hours After Flexible Dosing**

Flexible dose vardenafil, when dosed at 8±2 hours prior to sexual intercourse, demonstrated clinically and statistically superior efficacy (SEP3, SEP2, GAQ, IIEF-EF domain scores) compared with placebo in subjects with ED of broad etiology. Patients treated with vardenafil had clinically meaningful (≥18%) and statistically significant (p<0.001) improvements in their ability to maintain an erection to successful intercourse and achieve an erection sufficient for insertion compared with those receiving placebo at all treatment-week intervals examined over the course of the study. These improvements occurred within the first two weeks and were sustained through the 10 weeks of therapy. Over Weeks 2 to 10, success rates of SEP3 and SEP2 were 69% and 81% for vardenafil-treated subjects compared with 34% and 51% for placebo-treated subjects.

Success rates of SEP3 and SEP2 were examined by time study medication was taken to start of sexual activity (see Figure 9).
Mean success rates of SEP2 and SEP3 were higher for vardenafil-treated subjects compared with placebo treated subjects from 6 to 10 hours after intake of study medicine and for all attempts at penetration from 0-24 hours after intake of study medicine.

**Clinical Conclusions**
LEVITRA (vardenafil tablets) was effective in a broad range of patients with erectile dysfunction. LEVITRA was efficacious in patients regardless of etiology (organic, psychogenic, and mixed), duration of erectile dysfunction, age, and alcohol or tobacco use. LEVITRA was efficacious 8±2 hours after dosing. LEVITRA was effective in patients with a history of hyperlipidemia,
hypertension, obesity, diabetes mellitus (with HbA1c ≤ 12%), prostatectomy, and in patients with ED secondary to a traumatic spinal cord injury. LEVITRA demonstrated significant improvement in the percent of patients whose EF returned to normal (EF domain score ≥ 26) compared to placebo. Response to treatment may differ depending upon severity of disease. (See CONTRAINDICATIONS and WARNINGS AND PRECAUTIONS.)

DETAILLED PHARMACOLOGY

Pharmacodynamics

Studies of LEVITRA on Erectile Response: In patients with erectile dysfunction, erections considered sufficient for penetration (greater than or equal to 60% rigidity as measured by RIGISCAN® device [RigiScan Ambulatory Rigidity and Tumescence Monitor, Dacomed Corp., Minneapolis, USA]) occurred in 64% of men on 20 mg LEVITRA (vardenafil tablets) as early as 15 minutes post dosing compared to 52% of men on placebo. The overall erectile response of these subjects treated with LEVITRA became statistically significant compared to placebo at 25 minutes post dosing. In two separate double-blind, placebo-controlled crossover RIGISCAN® trials of men with erectile dysfunction of at least 6 months duration, 10 mg and 20 mg LEVITRA significantly improved erections initiated by visual sexual stimulation. Objective measurements of rigidity at the base and tip of the penis (by RIGISCAN®) during visual sexual stimulation showed significantly better results at all doses and time points with LEVITRA than with placebo. The mean duration of an erection, in response to visual sexual stimulation, sufficient for penetration was 54 and 67 minutes at the base and 39 and 45 minutes at the tip of the penis for the 10 mg and 20 mg doses of LEVITRA respectively, compared to 31 minutes at the base and 17 minutes at the tip for placebo.

The earliest elapsed time from dosing to attainment of an erection perceived to be sufficient for penetration and resulting in successful completion of intercourse was evaluated in a randomized, double-blind parallel group study in men with ED. The percentage of men reporting successful completion of intercourse after dosing with 10 mg or 20 mg vardenafil was greater than with placebo (p < 0.025) at all times ≥ 10 minutes and ≥ 11 minutes, respectively.

The amount of time from dosing (flexible dose) to attainment of an erection perceived to be sufficient for penetration and resulting in successful intercourse was evaluated in a randomized, double-blind, parallel group study in men with ED. The percentage of men reporting successful completion of intercourse 8 to 10 hours from dosing was greater with vardenafil compared to placebo (p < 0.001).

Studies of LEVITRA on Blood Pressure and Heart Rate: In a clinical pharmacology study of patients with erectile dysfunction, single doses of 20 mg LEVITRA caused a mean maximum decrease in supine blood pressure of 7 mmHg systolic and 8 mmHg diastolic (compared to placebo), accompanied by a mean maximum increase of heart rate of 4 beats per minute. The maximum decrease in blood pressure occurred between 1 and 4 hours after dosing. Following multiple dosing for 31 days, blood pressure responses were observed on Day 31 that were similar to those observed on Day 1. PDE5 inhibitors, including LEVITRA, may add to the blood pressure lowering effects of antihypertensive agents. (See ACTION AND CLINICAL PHARMACOLOGY and DRUG INTERACTIONS.)
A study was conducted in which the blood pressure and heart rate response to 0.4 mg nitroglycerin (NTG) sublingually was evaluated in 18 healthy subjects following pretreatment with 20 mg LEVITRA at various times before NTG administration. 20 mg LEVITRA caused an additional time-related reduction in blood pressure and increase in heart rate in association with NTG administration. The blood pressure effects were observed when 20 mg LEVITRA was dosed 1 or 4 hours before NTG and the heart rate effects were observed when 20 mg LEVITRA was dosed 1, 4, or 8 hours before NTG. Additional blood pressure and heart rate changes were not detected when 20 mg LEVITRA was dosed 24 hours before NTG (see Figure 10).

Figure 10: Placebo-subtracted Point Estimates (With 90% CI) of Mean Maximal Blood Pressure and Heart Rate Effects of Pre-dosing with 20 mg LEVITRA at 24, 8, 4, and 1 Hour Before 0.4 mg NTG Sublingually

Because the disease state of patients requiring nitrate therapy is anticipated to increase the likelihood of hypotension, the use of LEVITRA by patients on nitrate therapy or on nitric oxide donors is contraindicated. (See CONTRAINDICATIONS.)

Studies of LEVITRA on Cardiac Parameters: The effect of 10 mg and 80 mg vardenafil on QT interval was evaluated in a single-dose, double-blind, randomized, placebo- and active-controlled (moxifloxacin 400 mg) crossover study in 59 healthy males aged 45-60 years. This study also included another drug in the same class in approximately equipotent therapeutic doses (sildenafil 50 mg and 400 mg). The QT interval was measured at one hour post dose because this time point approximates the average time of peak vardenafil concentration. The 80 mg dose of vardenafil (four times the highest recommended dose) was chosen because this dose yields plasma concentrations covering those observed upon co-administration of a low dose of vardenafil (5 mg) and 600 mg BID of ritonavir. Of the CYP3A4 inhibitors that have been studied, ritonavir causes the most significant drug-drug interaction with vardenafil. The table below summarizes the effect on mean uncorrected QT and mean corrected QT interval (QTc) with different methods of correction (Fridericia and a linear individual correction method) at one hour post dose. No single correction method is known to be more valid than the other.
Table 13: Mean QT and QTc Changes in msec (90% CI) from Baseline Relative to Placebo at 1 Hour Post dose with Different Methodologies to Correct for the Effect of Heart Rate

<table>
<thead>
<tr>
<th>Drug/Dose</th>
<th>Heart Rate (bpm)</th>
<th>QT Uncorrected (msec)</th>
<th>Fridericia QT Correction (msec)</th>
<th>Individual QT Correction (msec)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Vardenafil 10 mg</td>
<td>5 (4, 6)</td>
<td>-2 (-4, 0)</td>
<td>8 (6, 9)</td>
<td>4 (3, 6)</td>
</tr>
<tr>
<td>Vardenafil 80 mg</td>
<td>6 (5, 7)</td>
<td>-2 (-4, 0)</td>
<td>10 (8, 11)</td>
<td>6 (4, 7)</td>
</tr>
<tr>
<td>Moxifloxacin 400 mg</td>
<td>2 (1, 3)</td>
<td>3 (1, 5)</td>
<td>8 (6, 9)</td>
<td>7 (5, 8)</td>
</tr>
<tr>
<td>Sildenafil 50 mg</td>
<td>4 (3, 5)</td>
<td>-2 (-4, 0)</td>
<td>6 (5, 8)</td>
<td>4 (2, 5)</td>
</tr>
<tr>
<td>Sildenafil 400 mg</td>
<td>5 (4, 6)</td>
<td>-1 (-3, 1)</td>
<td>9 (8, 11)</td>
<td>5 (4, 7)</td>
</tr>
</tbody>
</table>

Moxifloxacin produced the expected 5-10 msec prolongation, indicating that the study had the required sensitivity. Therapeutic and supratherapeutic doses of vardenafil and sildenafil produced similar decreases in uncorrected QT but increases in QTc interval. This study, however, was not designed to make direct statistical comparisons between the drugs or the dose levels. The actual clinical impact of these changes is unknown.

In a separate post-marketing study of 44 healthy volunteers, single doses of 10 mg LEVITRA resulted in a placebo-subtracted mean change from baseline of QTcF (Fridericia) correction of 5 msec (90% CI: 2,8). Single doses of gatifloxacin 400 mg resulted in a placebo-subtracted mean change from baseline QTcF of 4 msec (90% CI: 1,7). When LEVITRA 10 mg and gatifloxacin 400 mg were co-administered, the mean QTcF change from baseline was additive when compared to either drug alone and produced a mean QTcF change of 9 msec from baseline (90% CI: 6,11). The clinical impact of these QT changes is unknown. (See WARNINGS AND PRECAUTIONS, Congenital and Acquired QT Prolongation.)

Studies of LEVITRA on Exercise Performance in Patients with Coronary Artery Disease (CAD): In two independent trials that assessed 10 mg (N=41) and 20 mg (N=39) LEVITRA respectively, LEVITRA did not alter the total treadmill exercise time compared to placebo. The patient population included men aged 40-80 years with stable exercise-induced angina documented by at least one of the following: 1) prior history of MI, CABG, PTCA, or stenting (not within 6 months); 2) positive coronary angiogram showing at least 60% narrowing of the diameter of at least one major coronary artery; or 3) a positive stress echocardiogram or stress nuclear perfusion. The results of the 20 mg study are shown in Table 14.

Table 14: Effect of 20 mg LEVITRA on Exercise Treadmill Completion Times (Mean in Seconds ± S.D.)

<table>
<thead>
<tr>
<th>Parameter</th>
<th>20 mg LEVITRA (Mean in Seconds)</th>
<th>Placebo (Mean in Seconds)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Treadmill Exercise Time</td>
<td>414 ± 114 (N=36)</td>
<td>411 ± 124 (N=36)</td>
</tr>
<tr>
<td>Total Time to Develop Symptoms of Angina Pectoris (first awareness)</td>
<td>354 ± 137 (N=36)</td>
<td>347 ± 143 (N=36)</td>
</tr>
<tr>
<td>Total Time to ST-Segment depression (1 mm or greater change from baseline)</td>
<td>364 ± 101 (N=35)</td>
<td>366 ± 105 (N=36)</td>
</tr>
</tbody>
</table>
Studies of LEVITRA on Vision: Single oral doses of phosphodiesterase inhibitors have demonstrated transient dose-related impairment of colour discrimination (blue/green) using the Farnsworth-Munsell 100-hue test and reductions in electroretinogram (ERG) b-wave amplitudes, with peak effects near the time of peak plasma levels. These findings are consistent with the inhibition of PDE6 in rods and cones, which is involved in phototransduction in the retina. The findings were most evident one hour after administration, diminishing but still present 6 hours after administration. In a single dose study in 25 normal males, 40 mg LEVITRA, twice the maximum daily recommended dose, did not alter visual acuity, intraocular pressure, fundoscopic and slit lamp findings. (See ACTION AND CLINICAL PHARMACOLOGY.)

In another double-blind placebo-controlled clinical trial, at least 15 doses of LEVITRA 20 mg were administered over 8 weeks versus placebo. Statistically but not clinically significant changes in ERG flicker amplitude response and oscillatory potential amplitude were apparent when comparing LEVITRA to placebo-treated subjects. The FM-100 test did not detect any difference between LEVITRA and placebo-treated subjects. A suprathreshold dose of sildenafil (200 mg) resulted in statistically significant decreases in amplitude of the rod response, cone response, flicker response, and oscillatory potential as measured by percent change from baseline averaged over both eyes in recordings obtained 2 hours after dosing. The maximum response was not significantly affected.

Alpha-blockers: Since alpha-blocker monotherapy can cause marked lowering of blood pressure, especially postural hypotension and syncope, interaction studies were conducted with vardenafil in patients with benign prostatic hyperplasia (BPH) on stable tamsulosin or terazosin therapy, as well as in normotensive volunteers after short-term alpha blockade.

In two interaction studies with healthy normotensive volunteers, after forced titration of the alpha-blockers tamsulosin or terazosin to high doses over 14 days or less, hypotension (in some cases symptomatic) was reported in a significant number of subjects after co-administration of LEVITRA. Among subjects treated with terazosin, hypotension (standing systolic blood pressure below 85 mmHg) was observed more frequently when LEVITRA and terazosin were given to achieve simultaneous $C_{\text{max}}$ than when the dosing was administered to separate $C_{\text{max}}$ by 6 hours. Because these studies were conducted using healthy volunteers after forced titration of the alpha-blocker to high doses (subjects were not stable on alpha-blocker therapy), these studies may have limited clinical relevance.

Interaction studies were conducted with LEVITRA in patients with benign prostatic hyperplasia (BPH) on stable tamsulosin or terazosin therapy. When LEVITRA was given at doses of 5, 10 or 20 mg on a background of stable therapy with tamsulosin, there was no clinically relevant additional reduction in mean maximal blood pressure. When LEVITRA 5 mg was dosed simultaneously with tamsulosin 0.4 mg, 2 of 21 patients experienced a standing systolic blood pressure below 85 mmHg. When LEVITRA 5 mg was given with a six-hour dose separation from tamsulosin, 2 of 21 patients experienced a standing systolic blood pressure below 85 mmHg. In a subsequent study in patients with BPH, when LEVITRA 10 mg and 20 mg was dosed simultaneously with tamsulosin 0.4 or 0.8 mg there were no cases of standing systolic blood pressure below 85 mmHg. When LEVITRA 5 mg was given simultaneously with terazosin 5 or 10 mg, one of 21 patients experienced symptomatic postural hypotension. Hypotension was not observed when LEVITRA 5 mg and terazosin administration was separated by 6 hours. This should be considered when deciding about a time separation of dosing.
Concomitant treatment should be initiated only if the patient is stable on his alpha blocker therapy. In those patients who are stable on alpha-blocker therapy, LEVITRA should be initiated at the lowest recommended starting dose of 5 mg.

LEVITRA may be administered at any time with tamsulosin. When other alpha-blockers such as terazosin are co-administered with LEVITRA, a time separation of several hours should be considered.

**Pharmacokinetics**

LEVITRA is rapidly absorbed after oral administration, with a mean absolute bioavailability of about 15%. Its pharmacokinetics approximate dose-proportionality over the recommended dose range (5 mg, 10 mg, and 20 mg). Vardenafil is eliminated predominantly by hepatic metabolism. The elimination half-life is approximately 4-5 hours. Mean vardenafil plasma concentrations measured over 24 hours after the administration of a single oral dose of 20 mg vardenafil to healthy male volunteers are shown in Figure 11.

**Figure 11: Mean Plasma Concentration Curve for 20 mg Vardenafil after Oral Administration**

![Figure 11: Mean Plasma Concentration Curve for 20 mg Vardenafil after Oral Administration](image)

**Absorption:** Vardenafil is rapidly absorbed, with maximum observed plasma concentrations detected as early as 15 minutes post administration. In the fasted state, maximum plasma concentrations are achieved between 30 to 120 minutes (median 60 minutes) 90% of the time after oral dosing of vardenafil.

When LEVITRA is taken with a typical meal comprised of 30% fat, the rate and extent of absorption of vardenafil are unchanged compared to administration under fasting conditions. Consumption of a high-fat meal caused a reduction in $C_{\text{max}}$ of 18-50% without change in AUC; $t_{\text{max}}$ was delayed by one hour.

Absorption levels are unchanged with a moderate amount of alcohol.
**Distribution:** The mean steady-state volume of distribution ($V_{ss}$) for vardenafil is 208 L, indicating extensive tissue distribution. Vardenafil and its major metabolite, M-1, are highly bound to plasma proteins (about 95% for parent drug and M-1). This protein binding is reversible and independent of total drug concentrations.

Ninety minutes after administration of a single dose of 20 mg LEVITRA, less than 0.0002% of the administered dose is detected in the semen. The concentrations of vardenafil and its primary metabolite in the ejaculate 1.5 hours post dose were 49% and 71%, respectively, of the concentrations in plasma at the same time point. (See **ACTION AND CLINICAL PHARMACOLOGY**.)

**Metabolism:** Vardenafil is eliminated predominantly by hepatic metabolism via cytochrome P450 (CYP) 3A4, with some contribution from the CYP3A5 and CYP2C isoforms. The major circulating metabolite, M-1, results from desethylation at the piperazine moiety of vardenafil. M-1 is subject to further metabolism. The plasma concentration of M-1 is approximately 26% of the parent compound. This metabolite shows a phosphodiesterase selectivity profile similar to that of vardenafil and an in vitro inhibitory potency for PDE5 of 28% compared to vardenafil. Therefore, M-1 accounts for approximately 7% of the total pharmacologic activity.

**Excretion:** The total body clearance of vardenafil is 56 L/h and the terminal half-life is approximately 4-5 hours. After oral administration, vardenafil is excreted as metabolites predominantly in the feces (approximately 91-95% of administered oral dose) and to a lesser extent in the urine (approximately 2-6% of administered oral dose).

**Special Populations and Conditions**

**Pediatrics (< 18 years of age):** Vardenafil has not been evaluated in individuals less than 18 years old.

**Geriatrics (≥65 years of age):** A starting dose of 5 mg LEVITRA should be considered in patients 65 years and older. (See **DOSAGE AND ADMINISTRATION**.)

On average, elderly males (65 years and over) had a 52% higher vardenafil AUC (Area Under the Curve) and a 34% higher maximum concentration ($C_{\text{max}}$) than younger males (18-45 years). This difference was not statistically significant.

**Hepatic Insufficiency:** No dose adjustment is required in patients with mild hepatic impairment. In patients with mild hepatic impairment (Child-Pugh A), the AUC was increased 17% and the $C_{\text{max}}$ was increased 22%, compared to healthy male volunteers, following a 10 mg vardenafil dose. In patients with moderate impairment (Child-Pugh B), the AUC was increased 160% and $C_{\text{max}}$ was increased 133%, compared to healthy male volunteers, following a 10 mg vardenafil dose.

In patients with moderate hepatic impairment, a 5 mg starting dose of LEVITRA is recommended, which may subsequently be increased to a maximum dose of 10 mg, based on tolerability and efficacy. (See **DOSAGE AND ADMINISTRATION**.) Vardenafil has not been evaluated in patients with severe hepatic impairment.
Renal Insufficiency: No dose adjustment is required in patients with renal impairment. In patients with mild (creatinine clearance (CL_{cr} \geq 50-80 \text{ mL/min}), moderate (CL_{cr} > 30-50 \text{ mL/min}), or severe (CL_{cr} \leq 30 \text{ mL/min}) renal impairment, the pharmacokinetics of vardenafil were similar to that of a control group with normal renal function. Vardenafil pharmacokinetics have not been evaluated in patients requiring dialysis.

MICROBIOLOGY

Not applicable.

TOXICOLOGY

Vardenafil has been evaluated in a comprehensive series of toxicological studies, including in vitro and in vivo genetic toxicology assays, single-dose studies in mice and rats using both oral and intravenous routes of administration, repeated-dose studies in mice, rats, and dogs, reproductive and developmental studies in rats and rabbits, and life-time carcinogenicity studies in rats and mice.

Vardenafil was moderately toxic in mice and toxic in rats after oral and I.V. administration of single doses. The clinical signs observed were compatible with effects on the cardiovascular system. (See Table 16.) No adverse effects were observed in mice treated with up to 37 mg/kg (males) or 51 mg/kg (females) for 14 weeks, and no adverse effects were observed in rats treated for six months with up to 3 mg/kg (females) or 15 mg/kg (males), respectively. After 24-month daily treatment the no adverse effect level was established at 15 mg/kg (male rat) and 10 mg/kg (female rat), respectively. The no observed adverse effect level (NOAEL) for vardenafil in a study of dogs treated for 12 months was 3 mg/kg/day. (See Table 17.)

Vardenafil was administered to rats and mice for 24 months. These studies provide evidence that vardenafil is not carcinogenic. (See Table 18.) The systemic exposure achieved at the top dose was about 350-fold (rat) and 25-fold (mice) the exposure in humans at the maximum recommended therapeutic dose. No indication of genotoxicity or mutagenicity was found in a comprehensive battery of three in vitro assays and one in vivo assay. (See Table 19.)

Vardenafil did not impair either male or female fertility or early embryonic development as evidenced in a Segment I study in rats and Segment II studies in rats and rabbits (Table 20). Developmental toxicity (Segment II) studies in rats and rabbits did not reveal a specific primary teratogenic potential, although at high doses resulting in approximately 800 times the clinical exposure, maternal mortality accompanied by effects on intrauterine development were found. The NOAEL in the rat Segment III study was 8 mg/kg/day for maternal toxicity, and 1 mg/kg/day in the offspring, but the findings of developmental delay in the offspring do not raise specific concern in the context of the intended application of the drug in adult males. Vardenafil is secreted into the milk of lactating rats at concentrations approximately 10-fold greater than found in maternal plasma.

As expected for a PDE5 inhibitor, repeated dose toxicity studies in rats and dogs revealed cardiovascular effects as the prominent toxicological findings, which can essentially be related to the vasodilatory properties of PDE5 inhibitors including vardenafil. Other toxicological findings in the pancreas, exocrine glands, and the thyroid in repeated dose studies were confined to the rat (did not occur in dog and mouse). The effects observed in the rat have been described for other phosphodiesterase inhibitors. The key findings in long-term toxicity studies with the corresponding
doses and exposure parameters at the lowest observed effect level (LOEL) in chronic studies are given in Table 15.

Table 15: Key Toxicological Findings (Lowest Effect Level) in Experimental Animals with Vardenafil and Respective Multiples of Human Exposure at the Maximum Recommended Therapeutic Dose

<table>
<thead>
<tr>
<th>Species/Duration</th>
<th>Finding</th>
<th>Dose (mg/kg)</th>
<th>Multiples of Systemic Exposure Compared to Clinical</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td></td>
<td>$C_{\text{max}}$ (μg/L) AUC(μg*h/L)</td>
</tr>
<tr>
<td>Rat, 6 months</td>
<td>Heart (females only): myocardial fibrosis; Mortality (1 of 20)</td>
<td>75 (female)</td>
<td>564 640</td>
</tr>
<tr>
<td>Rat, 6 months</td>
<td>Thyroid (females only): colloidal alterations</td>
<td>75 (female)</td>
<td>564 640</td>
</tr>
<tr>
<td>Rat, 6 months</td>
<td>Exocrine glands: parotid gland: diffuse acinar hypertrophy; females only: diffuse acinar hypertrophy (submandibular gland)</td>
<td>75 (male) 265 218 75 (female) 564 640</td>
<td></td>
</tr>
<tr>
<td>Rat, 6 months</td>
<td>Pancreas: diffuse acinar hypertrophy</td>
<td>75 (male) 265 218 75 (female) 564 640</td>
<td></td>
</tr>
<tr>
<td>Rat, 6 months</td>
<td>Pancreas (males only): focal acinar atrophy</td>
<td>15 (male) 73 25 75 (female) 564 640</td>
<td></td>
</tr>
<tr>
<td>Rat, 6 months</td>
<td>Adrenal cortex: small vesicular vaculation (zona granulosa)</td>
<td>15 (male) 73 25 3 (female) 35 19</td>
<td></td>
</tr>
<tr>
<td>Rat, 2 years</td>
<td>Thyroid: follicular cell hypertrophy</td>
<td>75 (male) 390 362 25 (female) 239 229</td>
<td></td>
</tr>
<tr>
<td>Rat, 2 years</td>
<td>Adrenal cortex: small vesicular vaculation, diffuse hypertrophy (zona granulosa)</td>
<td>75 (male) 390 362 25 (female) 239 229</td>
<td></td>
</tr>
<tr>
<td>Rat, 2 years</td>
<td>exocrine glands: diffuse acinar hypertrophy (parotid and submandibular glands)</td>
<td>15 (male) 318 71 25 (female) 239 229</td>
<td></td>
</tr>
<tr>
<td>Dog, 1 year</td>
<td>Heart: peri-arterial edema</td>
<td>30 (male) 264 277 30 (female) 235 212</td>
<td></td>
</tr>
<tr>
<td>Dog, 1 year</td>
<td>decreased blood pressure, increased heart rate</td>
<td>10 (male) 101 71 10 (female) 83 64</td>
<td></td>
</tr>
</tbody>
</table>

Human PK data at the proposed maximum recommended therapeutic dose (20 mg/day) for comparison:

| Human (steady state) |                             |                 |                     |
|---------------------|------------------------------|-----------------|
|                     | 0.4 (male)                   | 1               |

**LEVITRA Product Monograph**
Table 16: Results of Single-Dose Acute Toxicity Studies

<table>
<thead>
<tr>
<th>Species</th>
<th>Route</th>
<th>Dose mg/kg/day</th>
<th>No. of Animals/Dose</th>
<th>Duration</th>
<th>Findings</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Single Dose Oral Toxicity in Mice and Rats</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
| Hsk WIN:NMR mice | Oral (gavage) | Mouse Rat | 5/sex | 1 day | LD<sub>50</sub> for male and female mice was 1000 mg/kg. LD<sub>50</sub> for male rats was 250 mg/kg and for female rats 190 mg/kg. Necropsies did not reveal any test article related changes.

The following signs of toxicity were seen in mice: decreased motility, staggering gait, abdominal position, tremor, tonic-clonic convulsions, laboured breathing, narrowed palpebral fissure.

Rats showed the following signs of intoxication: decreased motility, staggering gait, lateral position, abdominal position, hunched posture, laboured breathing, narrowed palpebral fissure, chromodacryorrhea. |
| Hsd Cpb: WU Rats | | | | | |

| **Single Dose Intravenous Toxicity in Mice and Rats** | | | | | |
| Hsk WIN:NMR mice | I.V. | Mouse Rat | 5/sex | 1 day | LD<sub>50</sub> for male and female mice was 123 mg/kg. LD<sub>50</sub> for male and female rats was 81 mg/kg. There were no test article related signs at the necropsies.

The following symptoms were observed in mice: decreased motility and/or increased motility, staggering gait, abdominal position, tremor, tonic-clonic convulsions, laboured breathing, narrowed palpebral fissure.

The corresponding findings in rats were: decreased motility, vocalization, staggering gait, abdominal position, tremor, tonic-clonic convulsions, laboured breathing, gasping, narrowed palpebral fissure. |
| Hsd Cpb: WU Rats | | | | | |
### Table 17: Results of Long-Term Repeated Dose Toxicity Studies with Vardenafil

<table>
<thead>
<tr>
<th>Species, Strain, Number/Sex/Dose</th>
<th>Dose (mg/kg BW/day) Route Duration of Treatment</th>
<th>Findings (at mg/kg/day)</th>
<th>NOAEL (mg/kg/Day)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Mouse (CD-1) 5</td>
<td>0, 40, 200, 1000 ppm PO (drinking water) equivalent to 0, 6.7, 36.6, 150.7 mg/kg (males); 0, 10.1, 51.0, 203.1 mg/kg (females) 14 weeks</td>
<td>Reduced water intake (females, 1000 ppm) increased urea (males, 1000 ppm); increased liver, heart, and spleen weight (males, 1000 ppm) without histopathological correlation.</td>
<td>37 (males) 51 (females)</td>
</tr>
<tr>
<td>Rat Wistar HsdCpd:WU 10</td>
<td>0, 6, 25, 100 PO (gavage) 4 weeks</td>
<td>Flushing (all doses); increased N- and O-demethylase activity with liver weight increase (100); thyroid follicular hypertrophy (100); slight myocardial fibrosis (females 100).</td>
<td>25</td>
</tr>
<tr>
<td>Rat (Wistar HsdCpd:WU) 10 (main)</td>
<td>0, 1, 5, 25, 125 PO (gavage) 14 weeks 0, 125 PO (gavage) 14 weeks followed by 4 weeks recovery</td>
<td>Increased mortality with myocardial necrosis (females, 125); reversible increase in water consumption (125). Reversible increase in WBC (125) increased N- and O-demethylase activity with liver weight increase (males 25; females 125); induction of mono-oxygenases and/or epoxide hydrolase (125); transient increase in T₃ (females 5; males 25); reversible thyroid follicular hypertrophy (females, 125); reversible acinar hypertrophy in parotid and submandibular glands (25); acinar hypertrophy in exocrine pancreas without progression (25); non-reversible slight increase in kidney weight (females, 25) reversible increase in urine volume (females, 125).</td>
<td>25</td>
</tr>
<tr>
<td>Rat (Wistar HsdCpd:WU) 10 (recovery)</td>
<td>0, 3, 15, 75 PO (gavage) 6 months</td>
<td>Increased mortality with myocardial necrosis (mainly in females, 75); thyroid colloidal alterations (females, 75); reversible acinar hypertrophy in parotid and submandibular glands (75); acinar hypertrophy in exocrine pancreas (75); focal acinar atrophy with interstitial fibrosis (males, 75); small vesicular vacuolation in the zone glomerulosa cells of the adrenal cortex (males, 15; females, 3); basophilic tubuli in kidneys (females, 75); increased relative kidney weight (males, 75; females, 15); increased relative heart weight (15); increased relative kidney weights (males, 15); increased relative adrenal weight (75); decreased plasma glucose and cholesterol; increased inorganic phosphate in plasma (females, 75); decreased ASAT and ALAT (males, 75); increased urine volume (75).</td>
<td>15 (males) 3 (females)</td>
</tr>
<tr>
<td>Rat (Wistar HsdCpd:WU) 50</td>
<td>Males: 0, 3, 15, 75 PO (gavage) Females: 0, 3, 10, 25 PO (gavage) 24 months</td>
<td>Increased water consumption (males, 75; females, 25); increased liver weight (males, 75; females, 25); acinar hypertrophy of parotic and submandibular glands (males, 15, 75; females, 25); diffuse hypertrophy and vacuolation of adrenal gland zona glomerulosa (males, 75; females, 25); thyroid follicular cell hypertrophy (males, 75); ovarian tubulostromal hyperplasia (females, 25); increased urine volume (males, 75; females, 25).</td>
<td>15 (males) 10 (females)</td>
</tr>
</tbody>
</table>
### Table 17: Results of Long-Term Repeated Dose Toxicity Studies with Vardenafil

<table>
<thead>
<tr>
<th>Species, Strain, Number/Sex/ Dose</th>
<th>Dose (mg/kg BW/day) Route Duration of Treatment</th>
<th>Findings (at mg/kg/day)</th>
<th>NOAEL (mg/kg/Day)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Dog (Beagle) 4</td>
<td>0, 3, 10, 30 PO (gavage) 4 weeks</td>
<td>Slightly increased liver microsomal enzyme activity (EROD) (30); flushing, decreased blood pressure; increased heart rate (10); subepicardial and pericardial edema (10); mild myocardial necrosis and fibrosis (30). Compared to control animals, decreased mean testis weight in vardenafil treated animals (LOEL: 3 mg/kg).</td>
<td>3</td>
</tr>
<tr>
<td>Dog (Beagle) 3</td>
<td>0, 1, 5, 12.5 intranasal 4 weeks</td>
<td>Adaptive local effects in the nasal cavity subsequent to vasodilating properties (12.5). Lower mean testis weight in control animals compared to vardenafil treated with no relationship to dose not considered to be treatment-related. All testes of all males (including control) were immature.</td>
<td>12.5</td>
</tr>
<tr>
<td>Dog (Beagle) 4 (main)</td>
<td>0, 1, 3, 10, 30 PO (gavage) 13 weeks</td>
<td>Decreased blood pressure, increased heart rate (10); increased incidence of mushy feces (10,30); reddened eyes and gums (10); slightly impaired body weight development (males, 30); increased N-demethylase activity (30).</td>
<td>3</td>
</tr>
<tr>
<td>2 (recovery)</td>
<td>0,30 PO (gavage) 13 weeks followed by 4 weeks recovery</td>
<td>Slightly increased heart and liver weight (males, 10); minimal to moderate periarteritis and/or arteritis of cardiac blood vessels (30).</td>
<td></td>
</tr>
<tr>
<td>Dog (Beagle) 4</td>
<td>0, 3, 10, 30 PO (gavage) 12 months</td>
<td>Decreased blood pressure, increased heart rate (10); increased incidence of mushy feces and mucosal redness (10); increased relative adrenal weight (females, 30); heart: peri-arterial edema (30).</td>
<td>3</td>
</tr>
</tbody>
</table>

### Table 18: Results of Carcinogenicity Studies with Vardenafil

<table>
<thead>
<tr>
<th>Species, Strain Number/Sex/ Dose</th>
<th>Dose (mg/kg BW/day) Route Duration of Treatment</th>
<th>Results</th>
<th>NOAEL (mg/kg/day)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Rat (Wistar HsdCpd:WU) 50</td>
<td>Males: 0, 3, 15, 75 PO (gavage) 2 years</td>
<td>No statistically significant positive linear trend in tumour incidence rates for either sex. The incidence of uterine adenocarcinomas in vardenafil treated groups did not exceed that of control animals [incidence: 12 - 6 - 7 - 12 (control - low - mid - high dose)]. See Table 17 for non-neoplastic findings.</td>
<td>75 (males) 25 (females)</td>
</tr>
<tr>
<td></td>
<td>Females: 0, 3, 10, 25 PO (gavage) 2 years</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Mouse (CD-1) 50</td>
<td>0, 40, 200,1000 ppm PO (drinking water) equivalent to 0, 7.0, 31.9, 150.5 mg/kg in males; equivalent to 0, 8.5, 42.1, 193.4 mg/kg in females 2 years</td>
<td>No statistically significant positive linear trend in tumour incidence rates for either sex.</td>
<td>151 (males) 193 (females)</td>
</tr>
</tbody>
</table>
### Table 19: Results of Mutagenicity/Genotoxicity Studies with Vardenafil

<table>
<thead>
<tr>
<th>Study Type</th>
<th>Species or Cell Type</th>
<th>Dose Levels</th>
<th>Results</th>
</tr>
</thead>
<tbody>
<tr>
<td>in vitro bacterial mutagenicity</td>
<td><em>S. typhimurium</em> TA 1535, TA 1537, TA 100, TA 98, TA 102</td>
<td>0, 16, 50, 158, 500, 1581, 5000 µg/plate</td>
<td>Negative</td>
</tr>
<tr>
<td>in vitro mammalian cell mutagenicity</td>
<td>Chinese Hamster Ovary V79/HGPRT</td>
<td>0, 2, 3.9, 7.8, 15.6, 31.3, 62.5, 125, 250, 500 µg/mL</td>
<td>Negative</td>
</tr>
<tr>
<td>in vitro clastogenicity</td>
<td>Chinese Hamster Ovary V79</td>
<td>0, 50, 100, 200, 400, 600 µg/uL</td>
<td>Negative</td>
</tr>
<tr>
<td>in vivo clastogenicity</td>
<td>Bone marrow erythroblasts of NMRI mice</td>
<td>0, 75, 150, 300 mg/kg BW</td>
<td>Negative</td>
</tr>
</tbody>
</table>

### Table 20: Summary of Reproduction and Developmental Toxicity Studies with Vardenafil

<table>
<thead>
<tr>
<th>Study Type</th>
<th>Species, Strain, Number/Sex/Dose</th>
<th>Doses (mg/kg/day) Route Duration of Treatment</th>
<th>Important Findings (at mg/kg/day)</th>
<th>No-adverse-effect-level (NOAEL) (mg/kg/Day)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Segment I Fertility</td>
<td>Rat (Wistar HsdCpb:WU) 24/sex/dose</td>
<td>0, 6, 25, 100 PO (gavage) Males: 4 weeks prior to and during mating Females: 2 weeks prior to and during mating through Gestation Day 7</td>
<td>Decreased body weight, increased water intake (25); salivation, decreased food consumption, (100); systemic tolerability (25). No findings with regard to fertility and early embryonic development.</td>
<td>100 (fertility)</td>
</tr>
<tr>
<td>Segment II Embryo-fetal development</td>
<td>Rat (Wistar HsdCpb:WU) 24 females</td>
<td>0, 3, 18, 100 PO (gavage) Gestation days 6-17</td>
<td>Maternal toxicity: increased mortality and other clinical signs of maternal toxicity, myocardial fibrosis (100). Embryo/fetal development: reduced placental and fetal weights, skeletal malformations (100) secondary to maternal toxicity.</td>
<td>18; 100 (specific teratogenic effects)</td>
</tr>
<tr>
<td>Segment II Embryo-fetal development</td>
<td>Rabbit (Himalayan CHBB:HM) 20 females</td>
<td>0,3,18,90 PO (gavage) Gestation days 6-20</td>
<td>decrease of food intake, amount of feces and urine (light yellow discolouration) (18); weight loss in one animal (90)</td>
<td>18</td>
</tr>
<tr>
<td>Segment III Pre- and post-natal development</td>
<td>Rat (Wistar HsdCpb:WU) 25 females</td>
<td>0,1,8,60 PO day 6 p.c. to 21 p.p.</td>
<td>F0: body weight loss (60); myocardial fibrosis (60) F1: decreased body weight, increased perinatal mortality (60); delay of physical development (8).</td>
<td>F0: 8 F1: 1</td>
</tr>
</tbody>
</table>
REFERENCES


PART III: CONSUMER INFORMATION

**LEVITRA®**
(vardenafil tablets)

This leaflet is part III of a three-part "Product Monograph" published when LEVITRA was approved for sale in Canada and is designed specifically for Consumers. This leaflet is a summary and will not tell you everything about LEVITRA. Contact your doctor or pharmacist if you have any questions about the drug.

Please read this information carefully before you start taking this medicine.

Keep this leaflet. You may need to read it again. If you have further questions, please ask your doctor or pharmacist.

**ABOUT THIS MEDICATION**

**What the medication is used for:**
LEVITRA is used in the treatment of erectile dysfunction. This is when a man cannot get or keep a hard, erect penis suitable for sexual activity.

**What it does:**
LEVITRA belongs to a class of agents known as phosphodiesterase type 5 (PDE5) inhibitors. Following sexual stimulation, LEVITRA works by helping the blood vessels in your penis relax, allowing blood to flow into your penis. This results in improved erectile function.

LEVITRA will not increase your sex drive. LEVITRA will only help you get an erection if you are sexually stimulated.

**When it should not be used:**
- If you are taking any medicines containing nitrates in any form. Similarly, nitrates must never be used by men who take LEVITRA. Nitrates are found in many prescription medicines used to treat angina (chest pain due to heart disease) such as nitroglycerin, isosorbide mononitrate and isorbide dinitrates. If you do not understand what nitrates are, or are unsure about whether a medication you are on is a "nitrate", ask your doctor or pharmacist.
- If you take LEVITRA with nitrate-containing medicines or any other nitrates (eg, amyl nitrite "poppers"), your blood pressure could suddenly drop to a life-threatening level. You could get dizzy, faint, or even have a heart attack or stroke.
- If you are taking cobicistat, indinavir, ritonavir, saquinavir, atazanavir, ketoconazole, oritraconazole. Cobicistat, indinavir, ritonavir, saquinavir, and atazanavir are used to treat HIV infections. Ketoconazole and itraconazole are used against fungal infections.
- If you have ever had an allergic reaction to any of the ingredients in LEVITRA. (See What the medicinal ingredient is and What the nonmedicinal ingredients are)
- If you have had an episode of vision loss in one or both eyes from a disease called non-arteritic anterior ischaemic optic neuropathy (NAION).
- Do not take LEVITRA with guanylate cyclase stimulators, such as riociguat.

**What the medicinal ingredient is:**
Vardenafil (as vardenafil hydrochloride)

**What the nonmedicinal ingredients are:**
The tablets contain the following non-medicinal ingredients: microcrystalline cellulose, crospovidone, anhydrous colloidal silica, magnesium stearate, hydroxypropyl methylcellulose, polyethylene glycol, titanium dioxide, yellow ferric oxide, and red ferric oxide.

**What dosage forms it comes in:**
LEVITRA is available as orange, round tablets marked with the BAYER cross on one side, and "5", "10" or "20" on the other. LEVITRA is available in 3 dosage strengths: 5 mg, 10 mg, and 20 mg, containing 5 mg, 10 mg, or 20 mg of the active ingredient vardenafil.

**WARNINGS AND PRECAUTIONS**

BEFORE you use LEVITRA talk to your doctor or pharmacist if you have or had any of the following conditions:
- Heart problems (irregular heartbeats, angina, chest pain, or had a previous heart attack). If you have heart problems, ask your doctor if your heart is healthy enough to handle the extra strain of having sex.
- Low blood pressure.
- Uncontrolled high blood pressure.
- Kidney dialysis.
- Severe liver problems.
- Blood problems, including sickle cell anemia or leukemia.
- Stomach ulcers or any type of bleeding problem.
- Deformation of the penis, Peyronie's disease or an erection that lasted more than 4 hours.
- If you are taking LEVITRA and experience temporary or permanent loss or change in vision, stop taking LEVITRA and call your doctor.
- Severe loss of vision due to damage to the optic nerve from insufficient blood supply, a condition called Nonarteritic Anterior Ischemic Optic Neuropathy (NAION). If you are taking LEVITRA and experience temporary or permanent loss or change in vision, stop taking LEVITRA and call your doctor.
- A rare, inherited eye disease called retinoschisis pigmentosa.

LEVITRA offers no protection against sexually transmitted diseases including Human Immunodeficiency Virus (HIV).

LEVITRA is not recommended for patients less than 18 years old.

Sudden decrease or loss of hearing has been reported in a few post-marketing and clinical trial cases with the use of PDE5 inhibitors, including LEVITRA. It has not been established whether these are related directly to the use of these medications or to other factors. If you experience these symptoms, stop taking LEVITRA and call your doctor.

INTERACTIONS WITH THIS MEDICATION

Drugs that may interact with LEVITRA include:

- nitrate-containing medicines or nitrates (eg, amyl nitrate “poppers”),
- cobicistat, indinavir, ritonavir, saquinavir, or atazanavir (used to treat HIV infections),
- ketoconazole, or itraconazole (used to treat fungal infections),
- erythromycin, clarithromycin, or gatifloxacin (used to treat infections),
- antiarrhythmic medications (for irregular heartbeat, eg, amiodarone, sotalol, quinidine, procaainamide),
- alpha-blockers (used to treat prostate problems or high blood pressure),
- riociguat (medicine used to treat high blood pressure in the arteries carrying blood from the heart to the lungs). Taking this medicine with LEVITRA could seriously affect your blood pressure (see “When it should not be used”).

LEVITRA might increase the amount of some medicines in your blood (sensitive P-gp substrates). Dabigatran (used to prevent blood clots from forming) is an example of these medicines. Do not consume grapefruit juice while taking LEVITRA.

LEVITRA should not be used together with other treatments of erectile dysfunction.

PROPER USE OF THIS MEDICATION

Usual dose:

- You must take this medicine exactly as prescribed by your doctor.
- Take your LEVITRA 25-60 minutes before sexual activity. However, sexual activity can be initiated as soon as 15 minutes and as long as 8-10 hours after taking LEVITRA.
- LEVITRA will only help you get an erection if you are sexually stimulated.
- LEVITRA tablets should be swallowed whole with some water. It does not matter if you take LEVITRA with or without food.
- LEVITRA is not affected by moderate amounts of alcohol (approximately 2 drinks of alcohol, wine, or beer in a 70 kg person). However, large amounts of alcohol can impair the ability to get an erection; therefore do not consume large amounts of alcohol prior to sexual activity.
- You should not take more than one dose of LEVITRA per day.
- Never change the dose unless your doctor tells you to.
- If you have to see a different doctor for any reason, be sure to inform him/her that you are taking LEVITRA.

This medicine has been prescribed for you personally and you should not pass it on to others. It may harm them, even if their symptoms are the same as yours.

Overdose:

If you have taken more LEVITRA than you should, contact your doctor or a Poison Control Centre immediately.

SIDE EFFECTS AND WHAT TO DO ABOUT THEM

As with most drugs, LEVITRA can cause some side-effects. These effects are usually mild to moderate in nature and do not last for a long time.

The most common side-effects are headache and flushing (a burning/warm sensation, usually in the face). Less commonly reported side-effects are indigestion, stuffy nose, sudden decrease or loss of hearing, and transient global amnesia (temporary memory loss). A small percentage of patients could experience abnormal vision (eg, decreased and blurred vision, increased perception to light, changes in blue/green colour discrimination) after taking LEVITRA. If this happens to you, do not operate a motor vehicle or any heavy machinery until the adverse effects disappear. If you have any of these adverse effects and they are severe or do not disappear, talk to your doctor or pharmacist.

- If you have an erection which lasts longer than 4 hours, you should contact a doctor immediately. If this is not treated immediately, permanent penile tissue damage and erectile dysfunction may result.
- If you have a heart condition and you experience any symptoms of a heart attack upon starting sexual activity (such as chest pains, irregular heartbeat, or shortness of breath), you should stop this activity and consult a doctor.
• If an allergic reaction occurs after taking LEVITRA, such as a rash, itching, swollen face, lips, throat, or shortness of breath, stop use and contact a doctor.

Sudden decrease or loss of vision has occurred rarely after the use of oral erectile dysfunction medications, including LEVITRA. It has not been established whether the loss of vision is related directly to the use of PDE5 inhibitors or other factors. People who have previously experienced a type of vision loss called Non-Arteritic Anterior Ischemic Optic Neuropathy (NAION) may be at an increased risk of reoccurrence of NAION. If you experience reduction or loss of vision in one or both eyes, stop taking LEVITRA and call your doctor.

SERIOUS SIDE EFFECTS, HOW OFTEN THEY HAPPEN AND WHAT TO DO ABOUT THEM

<table>
<thead>
<tr>
<th>Symptom/ Effect</th>
<th>Talk with your doctor or pharmacist</th>
<th>Stop taking drug and call your doctor or pharmacist</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Only if severe</td>
<td>In all cases</td>
</tr>
<tr>
<td>Priapism/erection lasting longer than 4 hours</td>
<td></td>
<td>✅</td>
</tr>
<tr>
<td>Symptoms of a heart attack upon starting sexual activity/chest pain, irregular heartbeat, shortness of breath</td>
<td></td>
<td>✅</td>
</tr>
<tr>
<td>Allergic reaction/rash, itching, swollen face, lips, throat, shortness or breath</td>
<td></td>
<td>✅</td>
</tr>
</tbody>
</table>

This is not a complete list of side effects. For any unexpected effects while taking LEVITRA, contact your doctor or pharmacist.

HOW TO STORE IT

LEVITRA should be stored between 15-30°C in the original package. Do not freeze.

Keep out of the reach of children.